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Sarcoma risk, disease severity and EXT mutation in hered-
itary multiple exostoses: a genotype-phenotype study
D.E.  PORTER1,  M.  FRASER1,  C.  DOBSON-STONE2,  L.
LONIE2, A.M. MONACO2, & A.H.R.W. SIMPSON1
(1Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic
Centre, 2Wellcome Trust Centre for Human Genetics, Headington, Ox-
ford, UK)
Introduction and Aims: Hereditary multiple exostoses (HME) is the
commonest  autosomal  dominant  orthopaedic  neoplastic  condi-
tion, affecting 1/50 000. Recent studies show that EXT1 (chromo.
8q) and EXT2 (chromo. 11p) are responsible for about 80% of
families.  Molecular studies  suggest  the  EXT1 (but perhaps not
EXT2) gene is  important  in progression of osteochondroma to
chondrosarcoma. In the only study of its kind, we aimed to deter-
mine whether disease severity (and sarcoma risk) is worse in EXT1
than EXT2 mutation carriers.
Methods: From  1996  to 2000,  172  affected individuals from 78
families with HME were screened for EXT mutation using fluores-
cent  single-strand  conformational  polymorphism  (f-SSCP)  and
DNA sequence analysis. Prior to mutation screening, a structured
history and clinical examination by two examiners allowed an HME
score to be calculated based on anatomical, functional and surgical
criteria (number of palpable osteochondromas, forearm and lower
leg deformity, radial head dislocation, range of movement at elbow,
forearm, wrist, knee, centile height, ulnar length as a proportion of
height, previous surgery). Statistical analysis was performed using
non-parametric (chi-square, Wilcoxon, Kendall’s)tests.
Results: 72 EXT1 and 70 EXT2 individuals were identified (no
mutation in 30). HME score ranged from 4 to 81 out of 100, and
was age- and sex-independent. Median HME score was signifi-
cantly greater in EXT1 than EXT2 carriers (median scores 44 vs
35, P<0.001). When broken down into anatomical, functional and
surgical components, each remained significantly worse in EXT1
carriers. Six sarcomas occurred, all in EXT1 carriers. Those with
sarcoma did not have significantly worse disease than other EXT1
mutation carriers.
Discussion: For the first time, EXT1 has been shown to produce
worse disease than EXT2 in HME. A greater risk of sarcoma may
result either from larger number of osteochondromas or because
EXT1 mutation is more crucial than EXT2 in the stepwise tumor-
igenic process. The identification of a higher-risk group (EXT1)
within the HME cohort may allow a better rationale for targetted
screening to seek worrying lesions prior to malignant change
Chromosome 9  alterations  and  p16  protein  expression  in
central chondrosarcomas
JUDITH V.M.G. BOVÉE1, DMITRI FEDOROV1, ANTHO-
NIE  H.M.  TAMINIAU2,  RAF  SCIOT3,  MARIA  DEBIEC-
RYCHTER4,  ANNE-MARIE  CLETON-JANSEN1  &  PAN-
CRAS C.W. HOGENDOORN1
(Departments of 1Pathology and 2Orthopaedic Surgery, Leiden Univer-
sity Medical Center, Leiden, The Netherlands; 3Department of Pathol-
ogy and  4Center  for  Human  Genetics, Leuven  University,  Leuven,
Belgium)
Aim: Chondrosarcomas are characterized by neoplastic growth of
cartilage forming tumor cells. The majority (75%) arise centrally,
in  the  medullar  cavity,  while  a  minority  develop  peripherally
secondary  to  an  osteochondroma.  We  previously  investigated
DNA-ploidy and loss of heterozygosity (LOH) at loci harboring
the EXT-genes (implicated in hereditary multiple exostoses), the
EXT-like genes, and at 9p21, 13q14, 17p13 and chromosome 10
in 12 central chondrosarcomas. Only three cases exhibited LOH,
with  9p21  involved  in  all  three.  At  9p21  the  p16  tumour
suppressor gene is located. Our goal was to further investigate this
chromosomal region and the expression of the candidate gene p16.
Methods: Cytogenetic analysis was performed on 16 central chon-
drosarcomas.  p16  immunohistochemistry  was  performed  on
formalin-fixed paraffin-embedded tissue of 16 cases to estimate the
effect of 9p21 alterations on p16 protein expression. 
Results:  Seven  central  chondrosarcomas  demonstrated  an
abnormal karyotype, five of which involved chromosome 9. Three
central  tumours  showed  involvement  of  the  9p12–22  region
including  t(9;10)(p22;q22),  add(9)(p21)  and  add(9)(p12).  For
two of them paraffin blocks were available revealing absence of p16
protein expression. Two tumours with –9 and del(9)(q12) demon-
strated p16 protein expression. In three chondrosarcomas previ-
ously demonstrating LOH at 9p21,  p16  protein expression  was
absent, while in six out of nine central chondrosarcomas without
LOH at 9p21, p16 protein expression could be demonstrated. 
Conclusions: The involvement of genes located at chromosome 9,
especially the 9p12–22 region, is suggested both by the previous
LOH results as well as the present cytogenetic studies. Since 9p21
alterations are highly associated with the absence of p16 protein
expression, this  suggests  an important  role  for  the  p16  tumour
suppressor gene in the development of central chondrosarcomas. 
Relevance of c-Kit as a prognostic marker and therapeutic
target in Ewing’s sarcoma
K.  SCOTLANDI,  R.  STRAMMIELLO,  M.C.  MANARA,  V.
CERISANO,  S.  BENINI,  M.  SERRA,  P.  NANNI*,  L.  LAN-
DUZZI§ & P. PICCI
(Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, §I.S.T.,
Istituto di Ricerche per la Ricerca sul Cancro, Unità Satellite di Biotec-
nologie di Bologna, and *Isituto di Cancerologia, Università degli Studi
di Bologna, Bologna, Italy)220 Abstracts
Ewing’s sarcoma (ES), the second most frequent primary tumor of
bone, shows a high tendency to give pulmonary and bone metas-
tases. In particular, skeletal involvement may appear, at the onset
or during the course of the disease, also in the absence of lung
metastases.  The  pathogenesis  of  these  lesions,  however,  is  still
poorly  understood  due  to  the  lack  of  appropriate  models.  We
described the ability of TC-71 and 6647 ES cells to metastasize to
the lungs and bones after intravenous injection of tumor cells in
nude mice.  Moreover, recent findings  have indicated in c-Kit  a
possible  ‘homing’  receptor  for  ES  cells.  Differently  from  other
musculoskeletal tumors, such as osteosarcoma and rhabdomyosar-
coma, ES cell lines showed high expression levels of c-Kit receptor.
Its ligand SCF, which is produced by human bone marrow stromal
cells and endothelial cells, confer a growth advantage to ES cells in
vitro, due to an increase in cell proliferation and to a reduction in
the apoptotic rate, and act as a potent chemoattractant for ES cells.
Down-modulation of c-Kit expression leads to a reduced chemo-
tactic and metastatic ability of ES cells. In this study, we analyzed
the prognostic relevance of the expression of c-Kit in a in a consec-
utive series of patients with ES of the extremities. The expression
of c-Kit in tumor specimens was assessed by immunohistochem-
istry in 34 non-metastatic, operable ES treated at a single institu-
tion. The c-Kit expression was analyzed in relation to event-free
survival. c-Kit was found to be expressed in 14/34 (42%) of the
cases. A widespread pattern of c-Kit expression in tumor cells at
diagnosis was significantly associated with a higher rate of systemic
relapse  (P=0.02). These findings support the  view of c-Kit as a
promising prognostic marker and therapeutic target in ES.
Genetic  imbalances  revealed  by  comparative  genomic
hybridization in Ewing tumors
TOSHIFUMI OZAKI1, MICHAEL PAULUSSEN2, CHRISTO-
PHER POREMBA3, CHRISTIAN BRINKSCHMIDT3, JULIO
RERIN2, SUSANNE AHRENS2, CHRISTIANE HOFFMANN1,
AXEL HILLMANN1, NORBERT LINDNER1, DANIEL WAI3,
KARL-LUDWIG  SCHÄFER3,  WERNER  BÖCKER3,  HER-
BERT JÜRGENS2, WINFRIED WINKELMANN1 & BARBARA
DOCKHORN-DWORNICZAK3
(Department of 1Orthopaedics, 2Pediatric Hematology and Oncology,
and 3Gerhard-Domagk-Institute of Pathology, Westfälische Wilhelms-
University, Münster, Germany)
Ewing  tumors  are  characterized  by  reciprocal  translocations
involving the  EWS gene on 22q12  fused to ETS transcription-
factor family members. Little is known about further aberrations
contributing to tumor development and progression.
Sixty-two  frozen  tumors  with  known EWS  rearrangements  (52
primary  tumors,  10  relapses)  of  ET  patients  registered  in  the
EICESS protocol were analyzed by comparative genomic hybridi-
zation. 
Average number of changes in 52 primary cases and 10 relapsed
cases was 3.6 and 4.7 per tumor (P=0.153). Frequent abnormali-
ties included gains of chromosomes 8, 12, 20, and 1q and losses of
16q and 19q. Neither number nor type of aberration was associ-
ated with histology, tumor size, disease stage, tumor localization,
or histological tumor response to chemotherapy. In 52  primary
tumors, 26 tumors with type I fusion (EWS exon 7 to FLI1 exon
6) and 26 tumors with other fusion types had an average of 2.4 and
4.8 aberrations per tumor, respectively (P=0.031). Combinations
of gains of chromosomes 8 and 12, gains of chromosome 20 and
either gains of 8q or 18q, and losses of 16q and 17p frequently
occurred.  The  cumulative  overall  survival  (OAS)  was  different
between 35 patients with <5 aberrations and 13 patients with ‡ 5
aberrations (P=0.009). Univariate analysis showed patients with
gains of 1q, 2q, 12, and 20 or losses of 16q and 17p had signifi-
cantly lower OAS than those without aberrations. By multivariate
analysis, loss of 16q (relative risk [RR]=0.190; P=0.0006) was an
independent prognostic factor.
In the development of ETs, the first step is likely to be a fusion
between the EWS gene and genes encoding members of the ETS
family  of  transcription  factors.  The chromosomal  imbalances  in
ETs are most likely secondary events involved in tumor progression.
uPA,  uPAR  and  PAI1  protein  expression  in  giant  cell
tumors
M.S. BENASSI, G. GAMBERI, P. RAGAZZINI, G. MAGAG-
NOLI, L. PAZZAGLIA, F. PONTICELLI, C. FERRARI & P.
PICCI
(Laboratory of Cancer Research, Rizzoli Orthopaedic Institute, Bolo-
gna, Italy)
Study: Giant cell tumor (GCT) is a bone neoplasm which is char-
acterized by the presence of large numbers of multinucleated oste-
oclast-like giant cells. Although GCT can be considered a benign
lesion, it exhibits high aggressiveness often associated with osteo-
lytic properties. The urokinase-type plasminogen activation system
has been described to be frequently implicated in the process of
degradation of the extracellular matrix during tumor cell prolifera-
tion and metastasis.  The system includes plasmin,  its precursor
plasminogen,  the  urokinase-type  plasminogen  activator  (u-PA),
and  the  plasminogen  activator  inhibitor  type  1  (PAI1),  which
modulates the catalytic action of uPA. Moreover the action of the
plasminogen activators is facilitated by the presence of receptors
for u-PA on cell surfaces (uPAR).
Aim; in this study we examined the expression of the uPA, uPAR
and PAI1 proteins in a series of 50 primary GCT and in eight lung
metastases, to evaluate if these proteins are associated with bone
distruption and metastasis in this form of cancer.
Method: the protein expression was studied with the avidin–biotin
immunoistochemistry method.
Results: our results showed that the incidence of the uPA, uPAR,
PAI1  protein  overexpression  was  significantly  higher  in  the
relapsed compared to the disease-free patients. 
Conclusion:  these  results  suggest  that  overexpression  of  these
proteins could be an additional factor required for the develop-
ment of invasion in the giant cell tumors.
M. Campanacci et al. Tumori 1989; 75: 389–95.
P.A. Andreasen et al. Int J Cancer 1997; 72: 1–22.
Proliferation versus apoptosis in Langerhans’ cell histiocy-
tosis
B. SCHOUTEN1, R.M. EGELER1*, P.J.M. LEENEN2, A.H.M.
TAMINIAU1 & P.C.W. HOGENDOORN1
(1Department of Pathology, Pediatrics and Orthopedics, Leiden Uni-
versity Medical Center, 2Department of Immunology, Erasmus Univer-
sity Rotterdam, The Netherlands)
Langerhans  cell  histiocytosis  (LCH)  is  characterised  by  an
abnormal proliferation of clonal dendritic cells;  the Langerhans
cell. These lesions may present amongst others in bones but other
sites such as skin or lung might be involved as well. On the basis of
clonality of the CD1a+ cell and the reports of familiar clustering in
LCH  the  hypothesis  was  made that  a genetic  mutation on  the
cellular level might be causative for LCH. 
Objectives of the study: Both osseous as well as skin cd1a+ lesions of
30 patients with LCH were studied with immunohistochemistry
for the expression of cell cycle-related gene products p53, mdm2,
p16, p21, rb and bcl2. 
Results: Twenty-seven of 30 cases studied showed staining of the
nucleus for p53. The overexpression was heterogeneous. All 27
cases  showed  strong  staining  of  the  nucleus  for  p21.  Both  the
Langerhans  cell  showed  staining  as  scattered  multinucleatedAbstracts 221
osteoclastic giant cells. All but  cases (27) showed strong, diffuse
staining of the nucleus and the cytoplasm for p16. Twenty-eight
cases were positive for staining with mdm2. the overexpression was
heterogeneous, ranging from small focal to strong diffuse staining.
All but one of the lesions stained positive for bcl2 ranging from
focal  small  staining  in  some  cases  to  diffuse  strong  staining  in
others. the staining was mostly cytoplasmic.
Conclusion: These findings suggest that the cellular mechanisms
that sense DNA damage, namely the p53–p21 pathway and the
p16–Rb  pathway  are  active  and  are  inducing  either  cell  cycle
progression and/or apoptosis. The overexpression of bcl2 might be
responsible for the arrest of apoptosis.
Analysis and prognostic value of the clinical and molecular
variables in a series of pediatric osteosarcomas
A. PATIÑO GARCÍA, E. SOTILLO PIÑEIRO, M. ZALACAIN
DÍEZ, L. GARATE ITURRIAGAGOITIA,* M. SAN JULIÁN*
& L. SIERRASESÚMAGA
(Department of Pediatrics and *Orthopaedics, University of Navarra,
Pamplona, Spain)
Paediatric osteosarcoma (OS) is well characterised at the clinical
and  pathological  levels;  nevertheless,  no  conclusive  molecular
markers  with  either  prognostic  or  diagnostic  value  have  been
described so far. At the molecular level, the paediatric OS is a puzzle
of  different  genetic  alterations,  namely  point  mutations  or  short
deletions affecting 13q (RB1 gene), 17p (TP53 gene), 3q and 18q.
Aim: To analyse the presence of genetic alterations at 13q, 17p, 3q
and 18q and to relate them with the prognosis of a group of paedi-
atric osteosarcomas. 
Subjects and methods: DNA was extracted from tumour tissue and
peripheral blood of 37 OS patients (16 females, 21 males). Micro-
satellite markers screened: introns 2 and 20 of the RB1 gene (13q),
intron 1 of the TP53 gene (17p), markers D3S1246 and D3S1212
(3q) and D18S42 (18q). The presence of point mutations affecting
exons 5–8 of the TP53 gene was screened by DGGE analysis.
Results: In our series, 35% of the OS tissues carried mutations at
the TP53 locus, and the analysis of microsatellite markers yielded
the following results. 
The marker of higher prognostic value in our series is the deletion
of the  RB1  gene, which is  associated with reduced disease-free
survival  (P=0.008).  Also  associated  with  poor  prognosis  and
reduced survival were the histological subtype (P=0.0066) and the
presence of metastasis at diagnosis (P=0.0006).
Conclusions: The presence of alterations at 17p, 13q, 3q and 18q is
a frequent event in the carcinogenesis of paediatric OS. The homo-
or hemizygous deletion of the RB1 gene, the presence of metastasis
and  the  chondroblastic  histology  are  associated  with  reduced
survival in our series. Other molecular parameters screened but
less  frequently  encountered  in  our  series  were  mutation  of
p21WAF1,  deletion  and  methylation  of  p16INK4  and  RB1
promoter methylation.
Prognostic value of P-glycoprotein in high-grade osteosar-
coma: a critical evaluation
MASSIMO  SERRA1,  GEMMA  REVERTER  BRANCHAT1,
KATIA  SCOTLANDI1,  GIUSEPPE  FILIPPONE1,  MARIA
CRISTINA  MANARA1,  STEFANIA  BENINI1,  STEFANO
FERRARI2,  FRANCO  BERTONI3,  CRISTINA  FERRARI1,
GAETANO BACCI2 & PIERO PICCI1
(1Laboratorio di Ricerca Oncologica, 2Servizio di Chemioterapia and
3Servizio di Anatomia Patologica, Istituti Ortopedici Rizzoli, Bologna,
Italy)
Multidrug resistance (MDR) associated with increased expression
of P-glycoprotein has been demonstrated to play a key role in the
chemotherapy unresponsiveness and clinical outcome of patients
with  high-grade  osteosarcoma.  However,  a  general  consensus
conclusion has been difficult to reach, owing to the variable results
published  by  different  research  groups.  Several  factors  may  be
taken  into  condideration  to  explain  conflicting  data,  including
differences in methods for sample preparation, fixation, immunos-
taining, analysis of immunohistochemical results, heterogeneity of
clinical treatments. Aim of this study was to assess P-glycoprotein
expression in different series of high-grade osteosarcoma patients
in  order  to  evaluate  the  influence  on  the  immunostaining  of
different methods for sample preparations and to determine the
prognostic value of P-glycoprotein in relation to the different drugs
employed in the chemotherapeutic protocols. By using immuno-
histochemistry with three different, mutually exclusive monoclonal
antibodies (JSB-1, MRK16, C494), P-glycoprotein expression was
analyzed  on  162  primary,  non-metastatic,  high-grade  osteosar-
comas, treated with chemotherapy protocols which included doxo-
rubicin,  methotrexate,  cisplatin  and  ifosfamide.
Immunohistochemical results were correlated either with clinical
outcome and sample  preparation. Experimental  data confirmed
that P-glycoprotein overexpression is one of the most important
adverse prognostic factors only in osteosarcoma patients treated
with chemotherapy protocols in which doxorubicin is the key drug.
Concerning the methodology, this study showed that: (1) sample
fixation and antigen preservation must be carefully controlled; (2)
tissue-specific  controls  and  standardized  human  osteosarcoma
MDR cell lines are essential for calibrating the detection method
and the subsequent scoring of clinical samples; (3) use of two or
more anti-P-glycoprotein antibodies improve the reliability of the
immunological detection. All these information must be taken into
consideration before considering the possible use of P-glycoprotein
as the basis for drawing innovative therapeutic regimens. 
Methylthioadenosine phosphorylase (MTAP) gene deletion
affects chemotherapy drug function in osteosarcoma
J.M. GARCÍA-CASTELLANO, C.P. JUNG, J.H. HEALEY, B.
MAZZA, A. HUVOS, J.R. BERTINO, P. MEYERS & R. GOR-
LICK
(Memorial Sloan-Kettering Cancer Center, New York, USA)
Aim of the study: Investigation of biological factors related to chem-
otherapy  resistance  might  identify prognostic  factors that  allow
stratification  of  patients  at  diagnosis  into  poor  and  good  risk
subgroups. The protein MTAP is a biological marker that might be
exploited  therapeutically.  MTAP  cleaves  a  subproduct  of
polyamine synthesis (MTA) into adenine and methylthioribose-1-
phosphate. It is known that the absence of MTAP function: (1)
makes the cells more susceptible to purine de novo synthesis inhib-
itors;  and (2) increases  the  MTA  cellular  concentration, which
exerts an apoptotic effect. There is no prior works showing in oste-
osarcoma cells the influence of MTAP status on cell behavior. We
hypothesized that: (1) osteosarcoma MTAP-negative cell lines are
more sensible to the action of purine de novo synthesis inhibitors;
and (2) there will be more apoptotic response in the these MTAP-
negative cells.
Methods:  Two  different  osteosarcoma  cell  lines  regarding  the
MTAP gene status  were  used: HOS, which has a homozygous
deletion of this gene, and U2OS, which is wild-type for this gene.
The response to a de novo synthesis purine inhibitor, L-alanosine,
TP53 RB1 D3S1246D3S1212 D18S42
Non Informative 37.% 23.3% 0.% 50.% 4.8%
Normal 37.1% 50.% 90.5% 45.% 66.7%
Altered 25.9% 26.7% 9.5% 5.% 28.6%222 Abstracts
and its IC50 was evaluated by means of a cytotoxicity assay. Cell
growth inhibition  was tested  by XTT/PMS assay after 72  h of
culture and expressed  as  percentage of  survival.  The  apoptotic
response of the cells was determined by staining nuclear chromatin
by means DAPI. The percentage of apoptosis was determined by
counting more than 7000  cells and scoring for the incidence of
apoptosis using a fluorescent microscope. The statistical analysis
was determined by the two-sided t-test.
Results:  In  the  cytotoxicity  assay,  the  IC50  of  HOS  cells  was
between 5- and 10-fold less than in the U2OS cells. Conversely,
the percentage of apoptotic cells was 5-fold greater in the HOS
cells than in the U2OS cells. The difference were in all cases statis-
tically significant (P<0.001).
Conclusions: Our results in osteosarcoma cell lines prove for first
time that: (1) MTAP-deficient cells are more sensible to the action
of  L-alanosine  than  the  MTAP-positive  cells;  (2)  apoptotic
response is more accentuated in the MTAP-deficient (HOS) than
in the MTAP-positive (U2OS). These results show that osteosar-
coma treatment and prognosis might  be improved regarding to
MTAP status.
Session 2: Case presentation
Osteogenic sarcoma in pregnant women
M.  SAN  JULIÁN1,  J.I.  BILBAO2,  G.  LOPEZ3  &  J.
CAÑADELL1
(Departments  of  1Orthopaedic  Surgery,  2Radiology  and  3Obstetrics,
University of Navarra, Pamplona, Spain)
A 30-year-old pregnant woman consulted at our Clinic after being
diagnosed with osteoblastic osteosarcoma in the distal right femur
in January 1990. The pregnancy was at the fifth month, without
problems. No metastases were found at the moment of diagnosis.
The doctors who made the diagnosis advised her an abortion as the
first step of the treatment, based both on the probabilities of influ-
ence of the pregnancy on the tumour growth and on the probabil-
ities  of  foetus  damage  due  to  chemotherapy.  In  addition  they
advised an amputation as local treatment for the tumour.
Possibilities:  (1)  abortion, amputation  and postoperative chemo-
therapy;  (2)  abortion, neoadjuvant chemotherapy,  limb  salvage
and postoperative chemotherapy as usual; (3) neoadjuvant chem-
otherapy as usual (cisplatinum, methrotrexate and doxorubicine),
abortion  and  limb  salvage  surgery,  and  postoperative  chemo-
therapy; (4) neoadjuvant chemotherapy excluding methrotrexate,
cesarean delivery after 9–12 weeks, limb salvage surgery and post-
operative chemotherapy; (5) neoadjuvant chemotherapy as usual,
limb  salvage,  postoperative  chemotherapy  and  normal  vaginal
delivery at the end of pregnancy if possible. 
Management of a limb-length discrepancy after intercalary
resection  of  the  femur  using  Ilizarov device  and  massive
bone allograft: a case report
P.A. DAOLIO, G. OLDANI & S. MAPELLI
(Surgical Oncology Department, G. Pini Orthopaedic Institute, Mi-
lano, Italy)
The authors present the case of an 8-year-old girl affected by oste-
osarcoma of the distal femur treated with polychemotherapy and
intercalary resection  of 15  cm. The reconstruction between the
residual  distal  epiphysis  and  diaphysis  was  performed  with  an
acrylic cement spacer fixed to the bone by a lateral blade-plate and
a medial right plate screwed in the cement.
Margins were wide. Necrosis was >90% (stage III, Rosen). Func-
tional result was good but with a final maximum flexion of the knee
of 50°.
The implant  failed after 7  years because of the  breakage of the
plates. The 15-year-old patient was CDF and had a 6.5-cm short-
ening of the limb. 
The discussed solutions were: implant of a modular knee pros-
thesis or of a massive allograft, but with these limb lengthening
would not have been possible. In order to solve the problem of
shortening, the authors considered the possibility of applying the
Ilizarov device, but its distal fixation should involve also the prox-
imal tibia with a worsening of knee function.
Finally the authors chose an original solution consisting in the fixa-
tion of the Ilizarov device distally, in acrylic cement, and proxi-
mally  in  the  femoral  diaphysis  after  the  removal  of  the
corresponding  portion  of  the  broken  plates  and  screws.  The
lengthening was perfomed between the femoral diaphysis and the
cement spacer and required 2 months. Then a massive allograft of
adequate length,  fixed  with  a  blade-plate,  was  implanted.  The
patient is still CDF and after 1 year fusion is achieved distally and
advanced proximally, maintaining the same ROM of the knee.
Session 3: Late effects of surgery, chemotherapy and radiotherapy in 
children with bone sarcomas
Comparison of the outcome of conventional osteosarcoma
at two specialist international orthopaedic oncology centres
S. FORD, A. SAITHNA, R.J. GRIMER & P. PICCI
(The Royal Orthopaedic Hospital, Oncology Service, Birmingham, UK)
Objective: To determine prognostic value of patient and treatment
parameters in management of osteosarcoma, and whether these
parameters are equally important across international boundaries.
Design:  Retrospective,  cross-sectional  study of  patients  (n=428)
diagnosed  with  around-knee  osteosarcoma,  between  1990  and
1997  at  specialist  orthopaedic  oncology  centres;  Birmingham
(UK) and Bologna (Italy). Disease-free survival (DFS) and overall
survival (OS) assessed by Kaplan–Meier, Fisher’s PLSD and Cox
proportional hazard regression.
Results: DFS and OS were 43 and 60% at 5 years in Centre 1 and
56 and 73% at Centre 2, respectively. Median survival was 108Abstracts 223
weeks at Centre 1 and 136 weeks at Centre 2. A significant differ-
ence  in  DFS  and  OS  was  demonstrated  between  the  centres
(P=0.0019  and  P=0.0280,  respectively).  The  most  important
prognosticators  were  raised  alkaline  phosphatase  (P=0.002  and
P=0.0019), degree of chemotherapy induced necrosis (P=0.0001
and P=0.0002)  and tumour  volume  >150  cm3  (P=0.0037  and
P=0.0057). The most significant combination of prognosticators
was  alkaline  phosphatase  and  tumour  necrosis.  Chemotherapy
regime was found to have significantly different outcome in DFS
and OS. 
Conclusions:  Prognosticators were shown to have differing value
across international boundaries. Chemotherapy regime was impli-
cated  as  a  major  factor  in  explaining  the  survival  difference
between centres.
Results of treatment of osteosarcoma in children and youths
according  to  the  EORTC  chemotherapy  regimen  in  the
Polish Paediatric Solid Tumours Group
W.  WOZNIAK,  J.  KIJOWSKI,  A.  SZAFRAÑSKI,  A.  CHY-
BICKA, J. BOGUSAWSKA-JAWORSKA, J. BOHOSIEWICZ, J.
KOWALCZYK, P. KOLECKI, M. KORZON, M. LIEBHART,
M.  RYBAK,  M.  WYSOCKI,  W.  GOLÊBIEWSKI,  B.  KA-
ZANOWSKA, M. RYCHLOWSKA, T. IZBICKI, M. KUCZAB-
SKI, J. WÊCLAWEK-TOMPOL, K. KATSKI, W. MADZIARA,
M. S. POPADIUK, BORUCZKOWSKI & M. LEDA
(Polish Pediatric Centers for Osteosarcoma Treatment)
Aim and methods: In the period 1991–2000, 98 patients with oste-
osarcoma were treated according to the EORTC chemotherapy
regimen  in  the  centres  of  the  Polish  Paediatric  Solid  Tumour
Group, mostly in the National Research Institute of Mother and
Child. In July 1998, a comparison trial started: its main goal is to
compare in a standardized way the efficacy of two osteosarcoma
chemotherapy regimens (EORTC and the adopted French HD-
MTX protocol (HD-MTX+DOXO/IFO+ETO). They were both
widely used in Poland but never in the same clinics, with a longer
‘tradition’ of the French one; therefore, we tried to find the better
(or at least not worse) one in terms of efficacy, safety and economy.
Until today, 28 patients were randomised to the EORTC treat-
ment in this trial.
Results: As the primary site, we encountered femur (53%), tibia
(28%), humerus (11%), pelvis (3%), cranium (2%), fibula (2%)
and radius (1%). Fifteen percent (14 patients) were diagnosed with
initial metastases. Ablative surgery was performed in 32 patients
(35%), whereas the rest (60–65%) have had different forms of limb
salvage or reconstructive surgery applied. Forty-one patients had
measurement  of  percentage  tumour  necrosis.  The  range  was
0–100%, median value was 60%. At this point no further conclu-
sions have been made; however, we quite doubt if the percentage
of tumour necrosis can be a useful prognostic factor.
Conclusions: In the whole group we encountered five relapses (one
patient  is  alive 25  months), two toxic  deaths. Generally, 63/98
patients (66%) remain alive. From 36 patients (29 of them with
localized disease) with a follow-up over 5 years, 17 are alive (47%),
and the patients with localized disease in this group have a survival
of 55% (16 patients). This gives an EFS 0.47 with a follow-up of
over 100 months.
Hypomagnesemia  secondary  to  chemotherapy  for  bone
sarcomas may cause neuropathy.
M.  GABOLI,  P.  BASTERO,  A.M.  ROMERO,  E.  RUZA,  A.
PATIÑO, A. DIEZ, S. RAGGIO, C. MATA, M. SAN-JULIÁN
& L. SIERRASESÚMAGA
(Departments of Pediatrics and Orthopedics, University of Navarra,
Pamplona, Spain)
Secondary effects  of bone tumor chemotherapy include tubular
injury of the kidney and metabolic toxicity, which may result in an
abnormal  plasmatic  level  of  magnesium.  On  the  other  hand,
peripheric neuropathy is a very well known side effect of many anti-
neoplastic drugs.
Aim:  To  assess  whether  hypomagnesemia  per  se  may  cause
polyneuropathy in patients who underwent chemotherapy for bone
sarcomas.
Methods:  126  clinical  records  of  patients  treated  with  chemo-
therapy for bone sarcomas (range 9–18 years) were analyzed retro-
spectively  for  chemotherapeutic  treatment,  plasmatic  levels  of
magnesium and neuropathy. Neuropathy was clinically defined as
persistence of at least one of the following: paresthesias and diffi-
culty of movement in the extremities, muscle cramps or pain.
Results:  43  patients  (34.12%  of  those  analyzed)  presented
hypomagnesemia in at least one determination during chemother-
apeutic  treatment:  18  showed  neuropathy;  two  had  seizures.
Hypomagnesemia  was  observed  in  these  20  patients  while
recording  the  neurological  symptoms.  Electroneurophysiology
studies  confirmed  neurological  alterations  in  nine  cases  and
showed a mixed polyneuropathy of the extremities, affecting pref-
erentially  hands  and feet,  mainly with  axonal damage. Supple-
ments of magnesium caused a rapid relief of the symptoms and
changes in the neurophysiology studies. Plasma levels of magne-
sium, without diet supplements, were found to be low for years
after the end of chemotherapeutic treatment. 
Conclusion: Hypomagnesemia, as a side effect of chemotherapeutic
agents  may  cause  polyneuropathy.  Routine  determinations  of
magnesium  plasmatic  levels  during  chemotherapy  allow  early
detection of hypomagnesemia that, promptly treated, may prevent
occurrence of polyneuropathy.
Analysis of the side and late effects of treatment and clinical
outcome  in  patients  with  osteosarcoma  and  Ewing’s
sarcoma
M.  GABOLI,  E.  RUZA,  A.  PATIÑO,  P.  BASTERO,  A.M.
ROMERO, A. DÍEZ, P.FIZ, T. BARBOSA, M. SAN-JULIÁN &
L.SIERRASESÚMAGA
(Departments of Pediatrics and Orthopaedics, University of Navarra,
Pamplona, Spain)
Improvement of survival of pediatric patients with bone tumors has
changed the course of these diseases and the pattern and type of
late effects of treatment.
Aim: To achieve a better knowledge of the clinical evolution of
children with bone tumors in order to improve their quality of life.
Methods: Clinical records of 70 children with osteosarcoma (OS)
(32 females and 38 males) and 44 children with Ewing’s sarcoma
(ES) (18 females and 26 males) were analyzed.
Results: Mean age at diagnosis was OS 13.9 years (4.01) and ES
13.3 years (4.3). Main primary tumor localizations in OS were
41.7% femur and 40.3% tibia; in ES were 13% femur, 20.4%
tibia and 18.5% extraskeletal. Median duration of treatment was
12 months (11–15) and 11 months (10.5–15.5) in children with
OS and ES, respectively; median time of hospitalization was 6.7
months (4.93–9.9) in OS patients and 5 months (3.4–7.6) in ES
patients. Mean disease-free survival time was 4.8 years (3.9) and
3.8  years  (3.6)  in  OS  and  ES  patients,  respectively.  The
following table shows the most frequent side effects and compli-
cations:
Conclusion: The knowledge of the clinical history of bone tumors in
children allows the early detection of side effects of treatment and
a better quality of life, during therapy and while in remission.224 Abstracts
Decision making in orthopaedic oncology
R.J. GRIMER & P. COOL
(Royal Orthopaedic Hospital Oncology Service, Birmingham, UK)
Aim: To provide a quantitative system for evaluation of the best
surgical intervention for patients with bone tumours. 
Method: Deciding what is best for an individual patient with a bone
tumour is becoming more difficult as the choices become greater.
One  has  to  weigh  the  advantages of  different  types  of  surgical
reconstruction with the time it takes to recover from the various
procedures and the risk of complications attached to each type of
surgical procedure both in the short and long term. Also, one has
to consider whether there is an increased risk to a patient survival
by performing a limb salvage procedure to try and preserve func-
tion as opposed to doing an amputation. In order to try and quan-
tify the risks and benefits of various types of procedure we have
developed  the  concept  of  FUNLYs  (FUNctional  Life  Years)
which is loosely based on the well established Quality Added Life
Year (QALY) used by health economists. The FUNLY uses the
MSTS score now available for many procedures and the published
risks of complications and further surgery for various procedures to
calculate relative values for different procedures. 
Results: FUNLY scores can be worked out for different tumour
types and different treatment methods. A computerised web-based
program will be demonstrated highlighting its use both in situa-
tions where there are multiple options for treatment and also in a
situation where there are large differences in function but signifi-
cantly greater risks of failure. For an osteosarcoma of the distal
femur results indicate: endoprosthetic replacement 5.38 FUNLYs,
allograft 5.21, rotationplasty 5.6, arthrodesis 3.6, distraction oste-
ogenesis 5.2, amputation 4.0.
Conclusion: FUNLYs offer a logical method of comparing different
interventions to highlight benefits and deficiencies of each. 
Distal  femur  intercalary  resection  and  reconstruction  in
high grade bone sarcoma
D. DONATI, S. GIACOMINI, E. GOZZI, M. MANFRINI & M.
MERCURI
(Oncologic Department, Instituto Ortopedico Rizzoli, Bologna, Italy)
The aim of the study was to define how much closer and safer we
can cut the osteotomy line in the distal aspect of the femur in inter-
calary resections.  We reviewed all the  cases  of high-grade bone
sarcoma located in the femoral diaphysis, selecting only those with
a distal cut within 8 cm from the knee joint. There were 58 patients
divided in three groups: Group A (mean age 22 years), 20 cases
performed from 1978 to 1987 and reconstructed with temporary
cementation or autografts. Group B (mean age 17 years), 25 cases
performed from 1985 to 1998 reconstructed with allograft alone
and Group C (mean age 12 years), 13 cases, same period, recon-
structed  with  allograft and vascularized fibula. In Group A the
osteotomy line was at a mean distance of 5.6 cm, and only in three
of them was the growth plate considered active at time of surgery.
The margins were judged inadequate in three cases, therefore two
recurred.  Eight  cases  survived  long  enough  for  evaluation;
however, four of them had a failure of the reconstruction and only
four are still working with satisfactory result (mean follow-up 182
months). In Group C, 5 cm mean distance from the joint, up to
nine cases (70%) were still skeletally immature at time of surgery.
Inadequate margins were noted in two cases, and one of these and
one other recurred (15%). Complications were infection in one
case, fracture in four cases (30%), and non-union in three cases:
three reconstructions failed (23%) while the other scored satisfac-
tory eight cases, and fair in two cases (mean follow-up 70 months).
In conclusion, saving the articular joint in distal femur resections
brings a high number of satisfactory results at follow-up. Compli-
cations and failure (including recurrence) occurred in a fairly high
number of cases. The choice of the vascularized fibula allows a
closer  cut to the growth plate; however, complications, such as
local recurrence and fracture, can be expected.
Late results in child knee reconstruction for bone sarcomas
M. MANFRINI, L. CAMPANACCI, M. DE PAOLIS, E. GOZ-
ZI, E. GUERRA & M. MERCURI
(Istituto Ortopedico Rizzoli, Bologna, Italy)
From 1984  to 1999, 214  children with a sarcoma of the distal
femur or proximal tibia (195 osteosarcoma, 15 Ewing’s sarcoma
and four MFH) were surgically managed at Istituto Rizzoli. A limb
salvage was performed in 153 cases (72 %), A1 rotationplasty in 33
cases (15%) while amputation was chosen in 28 cases (13%). Late
results were studied in 86 patients, alive more than 3 years after the
reconstruction  (mean  age  11;  range  7–13;  mean  follow-up  98
months). There were 32 arthrodeses, 20 prostheses, two allograft/
prosthesis composites, 14 osteoarticular allografts, while 18 cases
had intercalary juxta-articular reconstructions.  In the arthrodeses,
five  patients  had  a  secondary  amputation  between  5  and  144
months after the reconstruction because of early or late infection.
Three other cases were converted to prostheses after mechanical
failure. In other eight patients, at least one lengthening procedure
was performed. In the remaining cases the mean final shortening
was almost 8 cm in males and 4 cm in females. In prostheses, there
were one total femur lengthening, one standard total femur, 15
distal femur and three proximal tibia uncemented prostheses. In
five cases a smooth stem was used to minimize the damage to tibial
physis. Two patients were amputated because of late infections.
Three patients had stem fracture and were converted to total femur
prosthesis. Four patients had lengthening procedures on the pros-
thesis. The remaining knees had a mean shorthening of 5 cm in
males  and  3  cm  in  females.  Osteoarticular  allografts  were
implanted  both  in distal  femur or proximal  tibia  with  different
results.  All  six  proximal  tibias  failed  and  were  converted  in
composite prostheses. One late infection ended with the amputa-
tion. Two femur reconstructions were converted to prostheses. In
the six patients with femur allografts still in place, final shorthening
was 4.5 cm in males and 2 cm in females. In intercalary juxta-artic-
ular reconstructions (mean follow-up 90  months),  two patients
presented  postoperative  deep  infections:  one  had  the  implant
removed and the  bone reconstructed by Ilizarov technique, the
other one ended in above-knee amputation. In the 16 patients with
% OS ES % OS ES % OS ES
Myelotoxicity 95.6 90.9 Renal diseases 22.1 7.3 Sepsis 11.8 9.8
Infection 33.8 34.2 Osteomielitis 19.1 12.2 Psychiatric  8.8 9.8
Heart disease 27.9 31.7 Amputation  13.2 14.6 Hypoacusia 13.2 2.4
Neuropathy 23.5 19.5 Liver disease 17.6 9.8 Relapse 17.6 4.8
Months at diagnosis 21.4 16.7 Months in treatment 7.1 9.5 Months in remision 22 19.5
Lung months 68.2 46.3 Bone months 17.1 27.8 Death 17.2 20.4Abstracts 225
the original implant, the mean shorthening was 2 cm, both in males
and females.  Functional satisfactory  results  (Excellent  or Good
according to the Enneking System) increased from 25% in arthro-
deses to 55% in prostheses, 57% in osteoarticular grafts and 67%
in intercalary reconstructions.
The risk of amputation following limb salvage surgery with
endoprosthetic replacements
L. JEYS, R.J. GRIMER, S. CARTER & R.M. TILLMAN
(Royal Orthopaedic Hospital Oncology Service, Birmingham, UK)
Introduction: Endoprosthetic replacements (EPRs) are one of the
most commonly used types of limb salvage following surgical exci-
sion of bone tumours. The advantage of EPRs are their initial reli-
ability and the rapid restoration of function along with their ready
availability. The problems with eprs are the long-term problems of
wear,  loosening,  infection  and  mechanical  failure.  This  paper
assesses the risk of amputation following EPR.
Patient and methods: We retrieved data on all patients who had an
amputation after a previous EPR and looked at the reasons for this.
By comparing this  group with  patients who had not undergone
amputation we estimated the risks of amputation and stratified this
by type of prosthesis, diagnosis and complication.
Results: A total of 1262 patients have undergone epr surgery at our
centre in the past 34 years: a total of 6507 patient years of follow-
up; 112 patients have had subsequent amputation (8.9%). The
reasons for amputation were local recurrence in 71(64.4%), infec-
tion  in  38  (33.9%),  mechanical  failure  in  two  (1.8%)  and
continued pain in one case (0.8%). The risk of amputation was
greatest in the proximal tibia 15.5% (n=38/246), followed by pelvis
10.2%  (5/49),  and  femur  7.4%  (n=58/784),  whilst  the  risk  of
amputation was least in the humerus at 6.4% (n=11/182). The risk
of amputation was highest  in the  patients  diagnosed with  rarer
tumours (33% [n=4/12]), mfh (17.7% [n=9/51]) and soft tissue
sarcoma (14% [n=10/71]). The time to amputation varied from 2
days to 16.37 years, with a mean of 31 months. The median time
to  amputation  from  EPR  was  32  months  for  infection  and 13
months  for  local recurrence. The risk  of amputation decreased
with time, although 10% of the amputations took place more than
5 years after implantation.
Conclusion: The greatest risk of amputation is in the first 5 years
and is  due  to  local  recurrence,  whilst  infection  poses  the  next
greatest threat. The risk decreases with time. Attempts to control
both  local  recurrence  and  infection  will  decrease  the  need  for
amputation. Late failure of the EPRs, even in young patients does
not seen to be a major cause of amputation thus far.
Long-term results of expanding protheses for limb salvage
surgery of children
G. DELEPINE1, F. DELEPINE² & N. DELEPINE1
(1Oncologic Ped. Sce Hop., Bobigny, France, ²Rouen, France)
Introduction: Conservative surgery for young children with bone
sarcoma of lower limb remains a challenge. In 1985 we proposed
an expandable prosthesis and present here our long-term results. 
Patients: 44 patients (20 males and 24 females aged 4–28 years)
with tumors of the limbs were treated by our team between 1984
and 1999. Histology was mostly osteosarcoma (32) and Ewing’s
sarcoma (9). Locations were distal femur in 30, upper tibia in five,
total femur in five and proximal femur in four. Thirty were first
hand patients  (28 with localized disease and two already meta-
static) en bloc resection. The remaining 14 patients were referred to
us after induction therapy, with progressive disease, metastase (3)
or local recurrence (1). 
Method:  In  14  patients  the  expanding  prosthesis  was  inserted
immediately after the resection, in eight during the following year
and for the other 22 patients later to treat a length discrepancy.
One  hundred  and  seven  sequences  of  lengthening  have  been
performed in 40 patients. All patients were followed-up by their
surgeon and their chemotherapist every 3 months during 2 years,
then every 6 months for a further 2 years and yearly thereafter.
Results:  6  patients  died from  illness.  All  others  are  disease-free
survivors  with  a median follow-up of 91  months(maximal  192;
minimal  6).  Half  (22)  of  the  patients  are  adults.  The  average
lengthening is  4.07 cm (minimal 0.5; maximal 12). Half of the
patients had to be re-operated for complications. Deep infection
occurred in 10 patients (22%) resulting in amputation for three.
According to EMSOS criteria, the functional result is excellent in
14, good in 15, fair in 10 and poor in five.
Conclusion: Long-term results of lengthening prostheses confirm
that this procedure is an excellent alternative to amputation and
permits  a functional limb  in nearly 90%  of patients.  The most
severe complication is deep infection, underlining the interest of
previous generations on growth with  minimally  invasive length-
ening.
Infection after extensible  endoprosthetic  replacements for
bone tumours
M.V. BELTHUR, R.J. GRIMER, S.R. CARTER & R.M. TILL-
MAN
(The Royal Orthopaedic Hospital, Birmingham, UK)
Aim:  To  analyze the  risk  factors,  causes,  bacteriology  of  these
infections and to review our experience with the treatment of 19
patients with infected prostheses.
Materials and methods: 123 patients were treated with extensible
endoprostheses following resection of primary bone tumours of the
distal femur, proximal tibia, proximal femur and humerus between
1983 and 1998. Three types of prostheses, which differed in the
lengthening mechanism used, were implanted. Nineteen of these
were diagnosed to have deep infection. Details of the patients, clin-
ical  features  and  investigations  were  secured  using  the  bone
tumour unit database and using patient records. Bacteriology, risk
factors and causes were analyzed. Patients were divided into three
groups: group 1, five patients were treated with a single stage revi-
sion; group 2, 13 patients were treated with a two-stage revision
procedure; group 3, one patient was treated with a primary ampu-
tation.
Results: The overall incidence of infection was 15.45%. The inci-
dence of infection at the proximal tibia and distal femur was 28 and
14.3%,  respectively.  The incidence for the  three  types  of pros-
theses was 20.85% for the ball bearing (type 3), 18.75% for the C-
collar (type 4) and 16% for the worm wheel (type 5). The average
infection delay was 40.6 months. Staphylococcus epidermidis was the
most  common  organism  isolated.  The  most  common  clinical
features  were  pain  and  swelling  around  the  prostheses,  with
discharging  sinuses  being  more  common  around  the  proximal
tibia. Infection in almost all cases was immediately preceded by an
operative procedure or by a focus of infection elsewhere  in the
body. Group 1 patients: 20% success rate; Group 2, 84.6% success
rate. Amputation was the salvage procedure of choice for failed
revision procedures and was necessary in four out of five patients
in Group 1 and two out of 13 patients in Group 2. The mean
MSTS functional score was 83.3% (range 63–97%) in patients in
whom the infection was controlled.
Conclusion: The incidence of infection is high following extensible
endoprostheses, especially the proximal tibia. The type of pros-
thesis used and the number of lengthening procedures constitute
significant risk factors. Two-stage revision is successful in control-
ling infection in a majority of these cases. 226 Abstracts
Deep infection of tumor endoprostheses
G. GOSHEGER, D. BÜCHTER, A. HILLMANN & W. WIN-
KELMANN
(Department  of  Orthopaedics,  Westfälische  Wilhelms-Universität,
Münster, Germany)
In a retrospective study of 230 patients having undergone implantation
of a tumorendoprosthesis, we tried to figure out reasons for deep infec-
tion and looked for strategies to minimize deep infection of tumor endo-
prostheses: 145 MUTARSÒ endoprostheses and 85 KMFTRÒ
endoprostheses were implanted between March 1991 and December
1998. The results of the present study show that the use of gentamycin
collagen floss (SulmycinÒ implant) could significantly reduce infection
(P=0.03, c 2-test). The additional application of systemic antibiotics
(cephalosporines, third generation, e.g. RocephinÒ or FortumÒ ) could
further reduce the risk of infection. MandocefÒ (cephalosporinessecond
generation) was significantly less efficient. The postoperative antibiotic
regimen has to be sensitive especially against staphylococcus species
(69.7% of germs). Further factors which significantly influence the rate
of infection were the amount of blood loss, the operation time and the
diagnosis. Laminar air flow, the amount of preoperative leucocytes and
cementation of the endoprostheses had no significant influence on the
rate of infection (P>0.05).
Staged  revision  for  infected  reconstruction  after  limb
salvage surgery for bone tumors
N. FABBRI, D. DONATI, S. GIACOMINI, M. MANFRINI &
M. MERCURI
(Department of Musculoskeletal Oncology, Istituto Rizzoli, Bologna,
Italy)
Study aim: The purpose of this study was to evaluate the results of
a staged revision technique in the treatment of deep infection after
limb  salvage  surgery  for  bone  tumors  and  to  identify  factors
possibly affecting the outcome.
Materials  and  methods:  A  retrospective  study  of  19  consecutive
patients with an infected bone tumor reconstruction treated at our
Institution  in  the  period  1986–1997  was  undertaken.  All  the
patients underwent staged revision (two stages in 13 cases, three
stages in 5, four stages in 1) using one or more antibiotic-loaded
cement  spacers  after  debridement  and  partial  (10  cases)  or
complete (nine cases) removal of the original implant. Postopera-
tively, all the patients received oral or parenteral antibiotics for a
minimum of 4 weeks. Delayed reimplantation was performed in 15
cases, average time to reimplantation being 7 months (4–14). A
minimum  follow  up  of  3  years  was  available  in  all  patients.
Cultures identified S. epidermidis in 12 cases (63%), S. aureus in
four (21%), mixed organisms in two (11%), and were negative in
one case (5%), despite clinical evidence of infection.
Results:  At  a  minimum  follow-up  of  3  years,  13  patients  were
continuously infection-free (68%) while six relapsed (32%). Two
of the six relapses were cleared by amputation while four remained
infected.  Average  functional  result  of  infection-free  patients
according to the International Society Of Limb Salvage (ISOLS)
was 71% (21.2 points). Success rate was 89% (eight out of nine
patients) when a complete implant removal was accomplished and
only 50% (five out of 10 patients) with partial removal. Success
rate was 82% against methicillin-sensitive  organisms, 60%  with
methicillin-resistant and 0% when mixed organisms were present.
When  a  complete  implant  removal  was  combined  with  Staph.
epidermidis  a 100% success  rate was obtained. Success rate was
73%  using  vancomycin-impregnated  cement  spacers  and  50%
with other antibiotics. Treatment was successful in 100% cases (six
out of six patients) when negative cultures were obtained at the
time of reimplantation and in 50% cases (three out of six patients)
when cultures were positive.
Conclusions: Staged revision with antibiotic-loaded cement spacer for
infected bone tumor reconstruction is a demanding and expensive
technique requiring prolonged inability. Overall success rate in this
series approaches 70%. Complete removal of the infected implant,
microbiology, appropriate antibiotic selection, and negative cultures
before reimplantation are crucial. 
Our experience on postoperative radiationtherapy for low-
grade soft tissue sarcomas
R. CAPANNA, G. BELTRAMI, P. CALDORA, M. MELA°, P.
OLMI,° M. PERTICI°, R. DE FELICE & R. PASSALACQUA
(Chirurgia Ortopedica Ricostruttiva CTO, and °U.O. Radioterapia,
Florence, Italy)
Although wide excision alone is generally considered sufficient for
the local control of low-grade soft tissue sarcomas, adjuvant radia-
tion  therapy  being  recommended  only  for  inadequate  surgical
margins, recurrences may be observed following both wide and
marginal surgery. We present our experience on 77 cases of low-
grade  soft  tissue  sarcomas,  comparing  three  series  of  patients,
treated by different approaches: Group A (13 cases) surgery alone;
Group B (16 cases) surgery plus external radiation therapy; Group
C (48 cases) surgical excision, brachytherapy, and external beam
radiation therapy (45 cases) or surgery plus brachytherapy alone
(three  cases). The groups  were comparable for tumor size  and
surgical margins. At an average 48-month follow-up, metastases
occurred in seven cases (9%) of the overall groups. Local recur-
rences occurred in four patients of Group A (31%), no patients of
Group B and two patients of Group C (4%). The recurrences of
Group A were resected in three cases and amputated in one, while
that in Group C were resected in one and untreated in the other
(severe metastatic disease). In Group A, only one case of major
complications (one wound slought, healed after surgical reprises)
was  observed.  In  the  radiotherapy  groups  (B+C),  nine  major
complications  (14%)  were  found: three  fractures,  three  wound
slought, three nerve palsy. All these complications were observed
in patients in Group C. A successful conservative treatment was
done in seven of these patients, while two patients had to be ampu-
tated. In our experience, radiotherapy showed to be efficient in
improving the local control of low-grade soft tissue sarcomas (31%
of recurrence in Group A vs. 3% in Group B+C). No significant
differences on local control were observed between Group B and
C. Limb  salvage surgery had a failure rate of 8% (1/13) in the
surgery  alone  group,  while  it  was  3%  (2/64)  in  the  groups  of
patients treated by surgery plus radiotherapy. Our actual trend is
to use conventional postoperative radiotherapy.
Analysis on 141 consecutive soft tissue sarcomas, treated by
surgery plus brachytherapy
R. CAPANNA, G. BELTRAMI, D.A. CAMPANACCI, P. CAL-
DORA, L. CIAMPALINI, M. MELA°, P. OLMI° & M. PERTI-
CI°
(Department of Orthopaedic Oncology, °Department of Radiotherapy,
Florence, Italy)
Although  surgical  excision  plus  brachytherapy  and/or  adjuvant
radiotherapy is generally highly suggested to achieve local control
in soft tissue sarcomas, complications related to radiotherapy may
be more and more often observed. We report our experience on
141 patients, treated in our Center from July 1990 to November
2000. High-grade sarcomas were represented in 93 patients, low-
grade in 48. The upper limb was involved in 38 cases, lower limb
in 96, trunk in seven. All patients were treated by limb-sparing
surgery and had brachytherapy (average 35  Gy). Postoperative
external radiotherapy was associated in 128 cases, while preoper-
ative  radiotherapy  was  given  in  five  cases  (average  45  Gy);Abstracts 227
brachytherapy alone was employed  in eight  patients.  Adjuvant
chemotherapy (epirubicin plus ifosfamide) was associated in 31
patients. At an average follow-up of 54 months (from 4 to 120),
95 patients (67%) continued to be disease free, 11 (8%) had no
evidence  of  disease  (after  treatment  of  recurrence  or  distant
metastasis), 13 (9%) were alive with metastatic disease, 17 (12%)
were dead of disease,  five  (4%) were  dead from other  causes.
Local  recurrence  appeared  in  seven  patients  (5%):  five  were
treated by conservative surgery and two were amputated. Some
severe complications related to radiotherapy were observed in 14
patients (10%): fractures (5), wound slough (6), major nerve palsy
(3).  These  were  treated  conservatively  in  all  but  three  cases
(amputated). Regarding the overall clinical results (MSTS), 110
patients (78%) were rated as satisfactory, with 31 (22%) as unsat-
isfactory (18 fair, 13 poor). Despite some adverse local impact,
brachytherapy and external radiotherapy showed to be efficacious
as  adjuvant  in  achieving  a  good  local  control  of  soft  tissue
sarcoma.
Hemangioendothelioma of the mobile spine
S. BORIANI, A. GASBARRINI, S. BANDIERA, E. BERTOL-
DI, L. MIRABILE, G. BARBANTI & F. BERTONI*
(Department of Orthopedics and Traumatology, Ospedale Maggiore,
and *Istituti Ortopedici Rizzoli, Bologna, Italy)
Aim: Hemangioendothelioma (HE) of bone is a rare tumor (about
1%  of  primary  malignant  muscolo-skeletal  tumors)  originating
from angioblastic endothelial cells. A progression of malignancy
can be observed in the same tumor and in different entities from
low-grade  tumors,  to  differentiate  from  hemangioma,  to  high-
grade malignancies, to differentiate from true angiosarcomas. Ten
percent of HE arise from the spine, provoking vertebral collapse
and/or neurological signs at the onset. Early diagnosis and staging
are  critical  for  spine  function  and  quod  vitam  prognosis.  The
purpose of this study is to describe the different presentations and
evolution  of  these  entities  as  well  as  the  different  treatment
options.
Methods: Ten cases of HE of the mobile spine were retrospectively
reviewed: the series included four males and six females aged 21 to
64 years (average 30 years). Four cases arose from the thoracic
spine, five from the lumbar, one from the thoraco-lumbar junction.
Results: At the final clinical examination (follow-up 6–120 months,
average 46 months), six patients were continuously disease free,
two were  NED  (35–41  months  after  biopsy),  two  died  (17–84
months after biopsy). En bloc resection was performed in two cases
and allowed for complete local and systemic control of the disease
(follow-up 6–65). Intralesional excision was effective if associated
with radiation in five of seven cases. Multicentric onset, a charac-
teristic  feature of hemangioendotheliomas, was observed in one
case. 
Conclusions: En bloc resection is the treatment of choice for HE, it
is associated with the lowest recurrence rate, but dissemination of
the disease remains at risk.
Primary  spindle  cell  sarcoma  of  bone:  an  assessment  of
outcome
R. GRIMER, C. DOCKER & D. SPOONER
(The Royal Orthopaedic Hospital, Birmingham, UK)
Aim: To assess whether spindle cell sarcomas of bone behave like
other primary bone sarcomas.
Method and material: 193 patients with spindle cell  sarcomas of
bone have been treated over the past  25 years. Diagnoses have
included spindle cell sarcoma, MFH, leiomyosarcoma, fibrosar-
coma and angiosarcoma. The mean age was 47 years and 121 were
over the age of 40.  All but three  were high grade and 26  were
known to have metastases  at diagnosis. Ten arose secondary to
irradiation or Paget’s disease. The most common site involved was
the distal femur followed by the tibia, pelvis and humerus. Treat-
ment was with chemotherapy and surgery if suitable. Twenty-two
percent required an amputation. Outcome in terms of local control
and overall survival has been assessed to identify presenting and
treating factors of significance. 
Results: Overall survival was 52% at 5 years. Patients with meta-
static disease at diagnosis, with pelvic primaries and with radiation
induced sarcomas all had worse survival and local control. If these
patients  are excluded  then  survival  was  60%  at  5  years. Other
factors of prognostic significance were age (patients <40 did better
than those >40) and chemotherapy response. Local control was
better  after  amputation  than  limb  salvage  surgery  but  overall
survival  was  no  different.  The  histological  diagnosis  made  no
difference on outcome
Conclusion: Spindle cell sarcomas of bone are primary sarcomas
which do not fit into the categories of osteosarcoma, chondrosar-
coma or Ewing’s sarcoma. They tend to arise in an older age group
When treated by similar principles of chemotherapy and surgery
the outcome is similar to that of osteosarcoma. 
What is the price of surgery in patients with a bone tumour
located in the pelvis?
C.H.  HOFMANN1,  A.  HILLMANN1,  C.  GEBERT,  G.
GOSHEGER1, H. JÜRGENS2 & W. WINKELMANN1
(Departments of 1Orthopaedics and 2Hematology and Oncology. Uni-
versity of Münster, Germany)
Objective and methods: Surgical removal of pelvic tumours with or
without irradiation offers the best chance for long-term relapse-
free  survival.  Whereas  aggressive  surgery  will  improve  local
control, it also needs extensive rehabilitation and the functional
outcome may not be satisfactory. The aim of an prospective study
was to analyse the late functional outcome and the quality of life
assessment of patients with a musculo-skeletal tumour located in
the pelvis. The functional evaluation score of Enneking and quality
of life (EORTC-QLQ  C30) were determined in a cohort of 81
patients with a pelvic tumour.
Results: The median follow-up time was 48 months. The surgical
procedure includes hip transpositioning (HT), tumour resection
and endoprosthetic replacement (ER), and tumour resection and
reconstruction with allo or autograft (AR). The median Enneking
score of the whole group was 18/30 (range 2–30). In patients with
ER the median Enneking score was 9/30 (range 6–18) in compar-
ison to 19/30 (range 6–27) in patients with HT and 18/30 (range
6–30) in patients with AR. In the quality of life analysis, HT had
significant better results in social functioning mean 62.5 compared
to 30.3 in ER and 53.1 in AR. Asking for limitations in hobbies
work or their daily activities (RF2) HT faired better, mean 55.5
compared to 22.7 in ER an 46 in AR. Also in the global health
status (QL2) HT faired better mean 75 (ER 51.5, AR 69). In phys-
ical functioning, HT (mean 70)  and AR (mean 74) had better
results than ER (mean 54.5).
Conclusion: The hip transpositioning states a convincing surgical
procedure in patients with pelvic tumours. Better functional results
in  social  functioning,  role  functioning  and global  health  status
showed  that  there  is  no  psychosocial  outcome  disadvantage. A
resection and biological reconstruction in pelvic tumours improve
local control and the function and quality of life outcome will be
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Sciatic nerve resection: is that truly an indication for ampu-
tation? 
ISAAC MELLER, YEHUDA KOLLENDER & JACOB BICKELS
(Tel Aviv Sourasky Medical Center, Tel Aviv, Israel)
Background: En bloc resection of the sciatic nerve with a malignant
tumor of the pelvis or thigh was long considered an indication for
an  amputation  because  of  the  anticipated  poor  function.  The
authors describe the functional outcome of a group of patients who
underwent a limb-sparing surgery in spite of the need to sacrifice
the sciatic nerve.
Materials and methods: Between 1991 and 1999, the authors treated
12 patients who underwent limb-sparing resections of a malignant
tumor of the thigh, buttock, or pelvis, all of which necessitated en
bloc resection of a segment of the sciatic nerve with the tumor mass.
There were eight females and four males, ranging in age from 2 to
73 years (mean, 54 years).
Diagnoses:  Soft-tissue  sarcomas,  eight;  metastatic  bone  disease,
three; primary bone sarcomas, one.
Anatomic  locations:  Thigh,  seven;  pelvis,  four;  buttock,  one.
Follow-up ranged from 10 to 102 months (mean, 30 months).
Results: At the most recent follow-up evaluation, 11 patients were
ambulatory and only one patient was wheelchair bound. Of the
ambulatory  patients,  only  five  patients  required  a  walking  aid
(crutches or a cane); a long-leg brace was not required by any of
these patients. Although all patients had an anesthetic ipsilateral
foot, none had a pressure sore or required a secondary amputation.
All ambulatory patients were satisfied with the functional outcome.
Conclusion: Provided the femoral nerve is intact, the mere necessity
to resect the sciatic nerve with a given tumor of the pelvis or thigh
is not an indication for an amputation.
Inlay allograft reconstruction  after resection of low-grade
malignant bone tumours
A.H.M. TAMINIAU, R.L.M. DEIJKERS & R.M. BLOEM
(Leiden University Medical Centre. Leiden, The Netherlands)
Advances in MRI and histopathology made hemi-cortical tumor
resection with wide margins possible. 
Methods: We performed 22 hemi-cortical resections of low-grade
parosteal osteosarcoma (six), peripheral chondrosarcoma (six) and
adamantinoma  (10)  (proximal  femur  (two),  distal  femur  (six),
proximal tibia (10), proximal humerus (two). Follow-up was 64
months (range 27–135), mean age 25 years (range 16–60). Focal
intramedullary involvement was no exclusion criteria. The decision
to perform a hemi-cortical resection depended on the possibility to
obtaining  wide  surgical  intramedullary  margins  based  on  MRI.
Mean resection length was 10.9 cm (range 6–26). Resection of the
circumferential cortex varied from 50 to 80%. Intra-cortical resec-
tion of part of the opposing cortex was performed. twice. Fresh
deep-frozen inlay allograft (Netherlands Bone Bank Foundation),
precisely cut to the defect, fixed with lag screws or plate were used
on  impacted  allogenic/autogenic  cancellous  bone.  Follow-up
included radiological evaluation of primary site and chest. The allo-
graft–host union was evaluated (ISOLS). Functional results were
assessed at the latest follow-up using the MSTS system.
Results: Histology showed wide resection margins in 12 and marginal
in 10. Marginal resections toward soft tissue occurred to preserve
neurovascular structures (no adjuvant therapy). Marginal resection
towards bone occurred twice (local adjuvant: phenol/alcohol). No
signs of recurrence or metastasis were present at the latest follow-up.
All  allografts  showed  complete  incorporation between  6  and 30
months (mean 15). No allograft fracture, wound complication or
infection occurred. Fractures of host bone occurred 6 times (during
3 times and shortly after surgery 3 times), mainly at a sharp resection
corner, managed easily. The functional results were good or excel-
lent in all but one. The poor result was due to a stiff knee after
prolonged immobilisation (inter-condylar fracture).
Conclusion: Hemi-cortical resection of selected cases of low-grade
surface tumours, followed by inlay allograft reconstruction is a safe
and highly  effective procedure, not restricted by intramedullary
involvement and satellite lesions. Preoperative planning with MRI
is essential in assessing these wide resection margin. Although the
surgical  technique  is  demanding,  the  superior  clinical  results
makes it clearly worthwhile.
Prognostic factors in parosteal osteosarcoma
A.H.M.  TAMINIAU,  P.D.S.  DIJKSTRA,  H.M.  KROON  &
P.C.W. HOGENDOORN
(Departments of Orthopedic Surgery, Radiology and Pathology, Leiden
University Medical Centre, Leiden, The Netherlands)
Parosteal osteogenic sarcoma ( juxtacortical osteosarcoma) is a low-
grade malignant surface bone tumor that arises from the surface of
the metaphysis of long bones. A retrospective review was conducted
of 17 patients surgically treated between 1980 and 1998. The clin-
icopathological  features especially  in relation to  the  preoperative
MRI and CT findings were analysed. Surgical staging for stage IA,
IB, IIB resulted in nine, five and three patients, respectively. Local
recurrence developed in three patients (range 1–8 years postopera-
tively) and in one patient with long metastases. Local recurrence
occurred; in one patient after an open biopsy in a stage IB tumor
with  medulla  invasion  and with  a  positive  surgical  margin  after
resection, and two patients with a high-grade lesion of whom one
had an open biopsy. A wide, marginal and positive surgical margin
were found in nine, four and four patients, respectively. A dediffer-
entiated component was only in identified 1 patient and was not
diagnosed by MRI or CT. On MRI and CT, the median ratio of
circumferential  cortical involvement by the tumor was one-third.
Cross-sectional  imaging  demonstrated  medullary  involvement  in
five patients and compared to the histological findings a false-nega-
tive result in two patients. These findings, together with the esti-
mated volume of the tumor on CT and macroscopic measurements,
were not correlated to recurrence or medulla invasion. In contrast,
local recurrence presented in three out of eight patients with contact
between the tumor and the local neurovascular structures by MRI
analysis. In conclusion, medullary invasion and amount of cortical
involvement  were  not  poor  prognostic  factors.  However, a  poor
prognostic factor was a stage IIB lesion. If the radiological diagnosis,
nowadays based on dynamic MRI, is a low-grade parosteal lesion a
biopsy should not be performed routinely. 
Session 4: Neoadjuvant chemotherapy in soft tissue sarcomas
Preoperative  treatment  of  limb  soft  tissue  sarcoma  by
isolated  limb perfusion  (ILP) with TNF/melphalan versus
systemic  doxorubicin-based  chemotherapy:  a  non-rand-
omized comparison
I. MELLER, Y. KOLLENDER,  M. INBAR, J. ISSAKOV,  G.
FLUSSER & O. MERIMSKY
(Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel)Abstracts 229
Background:  Chemotherapeutic  cytoreduction  of  soft  tissue
sarcomas (STS) may permit  less  radical operations. In cases  of
large or multi-compartmental  deep masses, or involvement of a
neurovascular  bundle,  its  downsizing  is  required  before  limb-
sparing (LSS) surgery can be considered.
Patients: Thirty-six patients were suitable for either technique. All
were treatment (chemotherapy, radiotherapy, and surgery)-naive
patients. They had big and deeply seated AJCC stage IIIB limb
STS, with no evidence of systemic spread or local bone involve-
ment. All were candidates for amputation or extremely mutilating
surgery.  All  had  preserved  function of heart, lung, and kidney,
absence of vascular disease  in the  affected limb,  and signed an
informed consent. 
Methods: Retrospective, non-randomized study of results achieved by
isolated limb perfusion (ILP) with tumor necrosis factor- (TNFa ) and
melphalan versussystemic doxorubicin-based chemotherapy. In the ILP
group one ILP session was given preoperatively, and surgery was
performed after 6–8 weeks. In the chemotherapy group three courses of
chemotherapy were administered before surgery, which was performed
4 weeks later. Adjuvant chemotherapy was given according to the histo-
logical results of the preoperative treatment.
Results: For ILP group (23 patients): clinical RR 85%; LSS rate
100%; free margin rate 11/23; secondary amputation rate 2/23;
median percent necrosis 70; median DFS 25 months. For chemo-
group (13 patients): clinical RR 40%; LSS rate 100%; free margin
rate  10/13;  secondary  amputation  rate  0/13;  median  percent
necrosis 90; median DFS not reached yet. Differences in parame-
ters were statistically significant only for response rate.
Conclusions:  Neoadjuvant  doxorubicin-based  systemic  chemo-
therapy. for AJCC IIIB STS achieved at least a similar necrosis rate
as preoperative ILP with TNF/melphalan. The higher response
rate of STS to ILP did not lead to an improved necrosis rate nor to
an improved DFS. 
Preoperative ILP/TNF versus systemic ADR-based chemotherapy
Feasibility  of  pre-  or  post-operative  combined  chemo-
therapy (CT) and radiation-therapy (RT) in adult soft tissue
sarcomas of extremities or girdles (STS): a pilot study
F. GHERLINZONI*, A. DE PAOLI#, A. BUONADONNA#, S.
DEMITRI*, G. BERTOLA#, G. BOZ#, I. INNOCENTE#, M.
BERRETTA# & C. ROSSI#
(*Orthopaedics Department, Gorizia Gen. Hosp., Gorizia; #C.R.O.,
Aviano, Italy)
In the authors’ experience, adjuvant CT (inside a randomized trial)
induces a substantial benefit in terms of DFS and OS in the treat-
ment of STS (JCO 2001, in press). In that study, CT was planned
after any local treatment and recovery; the median time from diag-
nostic  biopsy to CT was 92  days (range 17–288). Therefore, a
multimodality  approach  with  concomitant  RT&CT,  whether
totally pre-op or post-op, was designed to define its feasibility &
toxicity.
Methods: Eligibility criteria were high grade (Grade 3–4 Broder),
sub-fascial spindle cell and polymorphous STS, size >5 cm or any
dimension if  relapse; age >16  to <65 years; PS <2 ECOG;  no
previous CT/RT. Treatment consisted of CT and RT concomi-
tantly administered. CT: epirubicin 60 mg/m2 i.v., days 1–2; ifos-
famide and mesna 3 g/m2 i.v., days 1–2–3 and G-CSF 300 m g/die
s.c. from day +9 to day +16; cycles were given every 21 days. RT
in pre-op setting: 22 Gy/11Fr between cycles 1 and 2 and between
cycles 2 and 3 of CT and a post-op boost of 16 Gy/8Fr, between
cycles 4 and 5 in case of positive margins. In post-op setting: all
three blocks of treatment were given.
Results: Seventeen patients have been enrolled, 10 as pre-op, seven
as post-op. Toxicity on 41 evaluable cycles of CT was as follows:
leucopenia G 3–4, 51%; thrombocytopenia G 3–4, 14%; anemia
G  3–4, 9%; non-hematological toxicity  G  3–4, 32% (stomatitis
4%, erithema 21%, proctitis 7%). All 10 patients treated in the
pre-op  setting  (three  still  on-going)  underwent  conservative
surgery; one patient had major complication (infected seroma). No
complications were noted in the post-op group.
Feasibility:  The  average median dose  intensity  of  CT was  84%
(60–100%).  RT was given at the  foreseen doses and treatment
time in 13/14 evaluable patients (compliance 93%).
Preliminary  conclusions:  In  the  pre-op  setting,  the  time  between
diagnostic biopsy and start of CT was 9 days (5–34). This inte-
grated combined modality approach allowed the administration of
intensified full doses CT combined with the adequate planned pre-
or post-op dose of RT. The study is ongoing in order to accrue the
foreseen number of patients.
Multiple primary malignancies in patients with soft tissue
sarcomas
O. MERIMSKY, Y. KOLLENDER, J. ISSAKOV, J.BICKELS,
G. FLUSSER & I. MELLER
(Tel Aviv Sourasky Medical Center, Tel Aviv, Israel)
Introduction: Modern cancer treatment has substantially increased
the survival of patients with various malignancies. One of the late
sequelae of a successful treatment is the development of a second
malignant  tumor.  However,  in  many  cases  of  second  primary
cancers,  exposure  to  chemotherapy  or  radiation  therapy  is  not
evident, and it should be postulated that the putative mechanism
for the development of the second tumor is different.
Methods: Retrospective search of data files of 610 patients with soft
tissue or bone sarcomas were treated by our team of Musculoskel-
etal Oncology from January 1995  through December  1999  was
performed.
Results: Out of 375 patients with STS, 28 (7.5%) developed other
malignant neoplasms either before or after its diagnosis. STS as the
first  tumor  occurred  in  14  patients.  The  second  tumor  types
included mainly STS and renal cell  carcinoma. The interval of
time between the diagnosis of the STS and the second malignancy
was 0–21 years. Three patients developed a third primary tumor
within  0–3  years  after the  diagnosis of  the  second  tumor.  The
median overall survival was >78 months. Fourteen patients had a
first primary tumor other than STS. The second tumors (mainly
STS) appeared within 0–27 years. The median overall survival of
the 14 patients in this group from the diagnosis of the first tumor
was >102 months.
Conclusions: The phenomenon of two or three primary neoplasms
in patients in whom one of the tumors was STS occurs in a rate of
7.5% — a significantly  higher rate than the occurrence of STS
among  the  general  cancer  population  (1%).  Most  of  the  cases
occur incidentally. The clinical implications are the need to search
for an occult second primary in patients with STS, as an integral
part of their follow-up. It is especially true in patients with primary
MFH who show a risk for developing a renal cell carcinoma. 
Neoadjuvant  chemotherapy  and  preop  irradiation  of  IIB
soft tissue sarcomas
M. HIZ, T. ÖGÜT, I. YÜCEL, N. MANDEL, F. DINÇBAS &
S. DERVISOGLU
(Cerrahpasa Faculty of Medicine, Orthopaedic Oncology Division, Is-
tanbul, Turkey)
Arm  Clinical 
RR (%)






ILP 85  100  11/23 2/23 70
ChT 40  100  10/13 0/13 90
P value <0.001 NS NS NS NS230 Abstracts
Aim:  Neoadjuvant  chemotherapy  and  preoperative  irradiation
prior to wide excision of IIB soft tissue sarcoma of the extremities
were applied to prevent the systemic metastasis and decrease the
local recurrence rate.
Subjects and method: Between October 1989 and October 2000, 42
patients (29 male, 13 female) with a mean age of 40.7 (14–65)
were treated with neoadjuvant protocol and all received wide local
excision with uncontaminated margins. All patients were operated
by  the  same  surgeon. Histological  distribution  was  28  synovial
sarcoma, nine malignant fibrous histiocytoma (MFH), two liposa-
rcoma, two malignant mesenchymal tumor, one leiomyosarcoma.
Localisations were: thigh 22, poplitea five, cruris six, knee one, foot
four, upper extremity three, axilla one. Epirubicin 100 mg/m2 and
Iphosphamide 4  m m/m2 with Mesna were applied to patients at
three cycles with 3-week intervals together with 5000 cGy preop-
erative irradiation. A shrinkage with an average diameter of 1.3 cm
was obtained. Wide excision was applied after the third cycle of
chemotherapy and the same chemotherapy regimen was continued
three more postoperative cycles regardless of the necrosis rate of
the tumor. Mean follow-up was 32 (5–98) months.
Results: Oncological result was 23 NED, seven AWD, 12 DOD of
the  mean 32-month  follow-up. Local recurrence rate was 4/42.
One patient had skeletal and one had brain metastasis. All recur-
rent patients developed lung metastasis also. All recurrent patients
were amputated and salvage chemotherapy was given, but all died
at mean 8 months (6–11). Of the 19 patients who developed lung
metastasis,  seven  received  metastasectomy.  Four  of  them  are
DOD. 
Conclusion: Neoadjuvant chemotherapy and irradiation provided
safe wide excision of huge IIB STS with 72% overall survival and
9.5% local recurrence at nearly 3 years follow-up.
The value of MRI in determining the presence of residual
tumour after the ‘whoops’ procedure
R.J. GRIMER, A.M. DAVIES,  A. MEHR, N. EVANS & P.B.
PYNSENT
(The  Royal  Orthopaedic  Hospital  Oncology  Service,  Birmingham,
UK)
Aim: Inadvertent excision of lumps which turn out to be soft tissue
sarcomas is still unfortunately quite common. It is known as the
‘whoops’ procedure. Determining whether there is residual disease
is key to deciding subsequent management. The value of MRI has
been assessed.
Method: All new patients referred to our unit with a potential
diagnosis  of  a ‘whoops’  lesion  were  routinely  reassessed  with
MRI 6  weeks  after the  initial  operation. Notwithstanding the
result of the scan, all patients underwent a further wide excision
of the involved area shortly after the MRI. The scans of these
patients have been reviewed and classified into positive, equiv-
ocal  or  negative. These  results  have been  compared  with  the
histological assessment of the re-excision specimen to determine
the  accuracy  of  MRI  in  predicting  the  presence  of  residual
tumour. 
Results: Of 887 patients with newly diagnosed soft tissue sarcomas
seen  in  an  8-year  period,  140  (11%)  had  previously  had  a
‘whoops’ procedure. Of these, 111 had re-evaluation MRI scans
and had also undergone a further re-excision. There was residual
tumour in 63 (57%) patients, whilst 48 (43%) had no residual
tumour.
The sensitivity of MRI in predicting tumour was 64%, but specif-
icity  was  93%.  Positive  predictive  value was 93%  and negative
predictive value 67%. Overall accuracy was 77%.
Conclusion:  MRI is useful in identifying residual tumour after a
whoops procedure but a negative result by no means excludes it.
Re-excision remains essential despite the MRI results in most cases
to ensure tumour clearance. Preventing the ‘whoops’ procedure is
clearly the best option of all!
Session 5: Metastatic disease: surgery vs radiotherapy in relation to life 
expectancy
Primary metastatic osteosarcoma: surgery and response of
the primary have major prognostic importance.
S. BIELACK, S. FLEGE, M. KEVRIC, D. BRANSCHEID, S.
LANG, H. JÜRGENS & A. ZOUBEK (FOR THE COOPERA-
TIVE OSTEOSARCOMA STUDY GROUP COSS)
(Department of Pediatric Hematology/Oncology, University Muenster,
Muenster, Germany)
Aim:  To define factors which might predict survival in primary
metastatic osteosarcoma.
Patients  and  methods:  All  patients  with  previously  untreated
(except primary surgery) high-grade osteosarcoma of the extremity
or trunk registered into a neoadjuvant COSS study before seven of
98 who presented with primary metastases were included into an
analysis  of  patient-,  tumor-,  and  treatment-related  factors  and
outcome.
Results: Two hundred and eleven patients with primary metastatic
osteosarcoma (histologically verified 128, proven by progression
54, diagnostic imaging only 29). After a median follow-up of 1.6
years for all patients and 3.7 years for survivors, 80 patients were
still alive, 34 of these in continuously complete surgical remission.
Actuarial overall survival at 5 years (5 yr OS) was 32%. (When the
29 patients with abnormal diagnostic imaging as the only sugges-
tion of metastases  were not included, 5  yr OS was only 27%.)
Among  pretreatment  variables,  site  of  the  primary  tumor  (189
limb: 5 yr OS 34%; 22 trunk: 13%) and of the metastases (155
confined to the lungs: 5 yr OS 38%; 56 extrapulmonary involve-
ment:  11%)  were  the  only  identified  factors  with  prognostic
impact. The 71 patients whose primary tumors responded well to
chemotherapy had a superior outcome (5 yr OS 53%) compared
to the 62 with poor response (24%). Ninety-three patients with a
macroscopically complete surgical remission of both the primary
and all metastases had a 5 yr OS of 51%, while almost none of the
patients with any remaining focus of proven tumor survived. 5 yr
OS  was  65%  for  46  patients  with  both  a  good  response  and
complete surgery.
Conclusion: In osteosarcoma, all efforts must be taken to remove
both  the  primary  tumor  as  well  as  all  metastasis.  Prognosis  is
improved in those patients who achieve a good tumor response to
chemotherapy.
Supported by Deutsche Krebshilfe
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Postoperative radiotherapy on indication is effective treat-
ment  of  cemented  hemiarthroplasty in  pathological  frac-
tures of the proximal femur 
P.D.S. DIJKSTRA, T. WIGGERS & H. BOXMA
(Orthopedic Surgery, Leiden University Medical Centre, Leiden; Sur-
gical Oncology, Daniel Den Hoed Cancer Center, Rotterdam; Surgery,
Medical Center Rijnmond-Zuid, Rotterdam, The Netherlands)
The routine use of radiotherapy after surgical fixation of a patho-
logical fracture is still controversial. In this study the indication for
radiotherapy after  surgery  was  persistent  or  recurrence  of  pain
postoperatively, and metastatic cortical lesion close to tip of the
stem. A retrospective analysis of pain relief, mobilisation, compli-
cations, radiotherapy after surgery for pathological fractures of the
proximal femur due to bone metastases in 50 patients was carried
out. Breast carcinoma was the primary tumor in the majority of the
patients.  These  patients  with  52  fractures,  40  actual  and  12
impending,  were  treated  with  cemented  hemiarthroplasty.  The
patient  survival  rate  was  55%  after  6  months.  Pain  relief  was
achieved in 90% of the patients. Forty-four patients (85%) were
able to walk in 7 days postoperatively. There was one local compli-
cation. In five cases the endoprothesis failed (range 1–55 months);
luxation,  refracture  (n=2),  and  loosening  (n=2).  Nine  patients
received postoperative radiotherapy (median 24 Gy, range 20–30
Gy), four  within  8  weeks after  surgery,  and four  of these  nine
patients had failure of endoprothesis. If pain recurrence was the
indication  for  postoperative  radiotherapy  all  patients  sustained
pain reduction. Two-thirds of the patients received preoperative
radiotherapy (median 24 Gy, range 8–30  Gy), in 12% of these
patients radiotherapy was also performed after surgery. Preopera-
tive radiotherapy had no correlation to failure of device or pain
recurrence.  In  conclusion,  our  results  show  that  not  routinely
performing radiotherapy (24 Gy) after cemented hemiarthroplasty
for  the  treatment  of  pathological  fractures  is  a  safe  method  to
improve  quality  of  life.  There  is  a  need  for  a  prospective
randomised study about the use of routine postoperative radio-
therapy.
Metastatic disease after primary sarcoma and carcinoma: a
need  for  a  standardized  surgical  therapy  regimen  (the
University of Muenster experience)
N.J. LINDNER, G. GOSHEGER, T. OZAKI, C. HOFFMANN,
C. GEBERT, R. RÖDL, F. BÖTTNER & W. WINKELMANN
(University of Münster, Germany)
Aim: The prognosis of metastatic disease in bone is poor, but a
proportion of patients may survive for several months or even years
and will require active treatment. The aim of this study was to eval-
uate indications, various strategies of surgical treatment of bone
metastases  after sarcoma and carcinoma and their outcome and
influence on the course of the disease.
Methods: In a retrospective study we analyzed 184 patients with
bone  metastases.  Parameters  were  primary  tumor,  localization,
type  of  metastases,  indication  for  operative  treatment,  type  of
surgery performed and pre- and postoperative adjuvant treatment.
Complications and results of treatment including pain, mobility
and quality and duration of life were evaluated.
Results: In 157 patients one procedure was indicated, 13 patients
had two operations. We found a high rate of primary unknown
tumors (50, 27.2%) and osteolytic metastases (159, 86.4%). Most
frequent indications were pain (129, 70%) prophylactic fixation
(75, 40.7%) and fracture (46, 25%). Operations were posterior
stabilization (39, 24.8%), tumor prosthesis (35, 22.2%), osteosyn-
thesis with curettage and cementation (19, 12.1%) and curettage
and cementation (19, 12.1%). Adjuvant regimens like pain-, radio-
and  chemotherapy  were  performed  pre-  and  postoperatively.
Preoperatively 41 (26.1%) patients received radiotherapy and 17
(10.8%)  chemotherapy.  Postoperatively  64  (40.7%)  patients
received  radiotherapy,  48  (30.5%)  analgesic  therapy  and  25
(15.9%)  chemotherapy.  Complications  delaying  postoperative
recovery were high  and found in 52  (33.1%)  patients.  Clinical
mortality was 4.4% (seven). Primary skeletal stability was found in
116  (73.8%)  cases,  mildly  impaired  function  of  the  affected
extremity in 93 (59.2%) and 73  (46.4%) were completely pain
free.
Conclusions:  With  a  rational  standardized  surgical  strategy  in
combination with adjuvant treatment most patients get an accept-
able stability and function of their extremity or spine and reach a
better physiological and psychological constitution as well as local
disease control. 
The  effectiveness  of  surveillance  programmes  in  patients
with sarcoma
R.J. REES, L. JEYS, P. COOL & R. GRIMER
(Royal Orthopaedic Hospital, Birmingham, UK)
Purpose:  To  assess  the  efficacy  of  the  current  surveillance
programme for patients with sarcoma. Surveillance programs are
important to enable both local recurrence and metastatic disease to
be picked up earlier, which could improve survival. The medical
literature  is  lacking  with  regards  specific  guidelines  for  surveil-
lance. Whooley et al.1 reported their method of surveillance in 176
patients with soft tissue sarcoma.
Methods: We undertook a prospective analysis of all patients with
sarcoma treated between 1990 and 1995.The patients routinely
enter a surveillance programme which consists of regular clinical
evaluation, CXR and radiological imaging.
Results: Seven hundred and twenty-six cases of sarcoma with mean
follow up 8.4 years (range 6.2–11.3). Local recurrence occurred in
14%  of  cases  and  34%  developed  metastases.  The  cumulative
survival at 10 years was 59% (5 years 66%). Forty-six percent of
the deaths were directly attributable to metastases. Clinical evalu-
ation and CXR were found to be valuable tools for detecting local
recurrence and metastases. The role of MRI and CT in surveil-
lance was unclear. 
Conclusion: Surveillance programmes are valuable in the manage-
ment of patients with sarcoma but their precise role needs to be
well defined.
Bone metastases  in  breast carcinoma: therapy and  prog-
nosis
H.R. DÜRR, P.E. MÜLLER, T. LENZ, V. JANSSON & H.J.
REFIOR
(Department  of  Orthopedics,  Ludwig-Maximilians-University  Mu-
nich, Germany)
Aim of the study: Bone metastases are commonly found in breast
cancer patients. In this retrospective study, we evaluated the effect
of surgical therapy on a series of 70 patients with breast cancer who
were surgically treated for metastasis of the bone.
Methods: The patients’ age, treatment of the primary tumour, time
of appearance of bone and visceral metastases, clinical symptoms,
surgical treatment, complications, and survival were reviewed. The
most common locations of bone metastasis were the spine (n=29),
and the proximal femur (n=27). Pathological fractures were found
in the spines of 17 patients and in the extremities of 22 patients.
Ten patients showed neurological impairment. At presentation, 19
patients had a singular osseous lesion, 19 patients showed multiple
bone lesions, and 32 patients had additional visceral involvement.
The  surgical  procedures  included  60  palliative  procedures,  six
radical resections and four biopsies. Presently, 56  patients have232 Abstracts
died of their disease. In the 14 surviving patients, the mean obser-
vation period is 35.6±40.1 months.
Results: No patient had local recurrences or local tumour progres-
sion.  Of  the  six  patients  with  radically  resected  solitary  bone
lesions, five developed systemic progression of the disease. Of the
19 patients with presumably solitary bone lesions, five appear to be
free of tumour at present. Of the 19 patients with multiple bone
lesions and initially no visceral tumour spread, only two patients
are still alive. Of the 32 patients with additional visceral metastases
at surgery, four are alive with the disease. For the entire group, the
survival rate was 59% after 1 year, 37% after 2 years, 13% after 5
years and 7% after 10 years. The only two independent factors that
were associated with survival were the extent of the disease and the
duration of symptoms due to bone metastasis.
Conclusions: Orthopaedic surgery in patients with bone metastases
secondary  to  breast  cancer  and  bone  metastases  should  be
confined to those patients whose impending or actual fractures or
neurological complications force surgical therapy. The comparably
long survival rate in this group of patients and the proven prog-
nostic factors associated with a particular patient should be taken
into  consideration  when  deciding  which  intervention  is  appro-
priate.
Resection  and  reconstruction  versus  transfocal  internal
stabilization in the treatment of metastatic bone diseases
I.  ANTAL,  T.  L_RINCZ,  M.  PATCZAI,  A.  SÁRVÁRY,  P.
SZÉPHALMI & M. SZENDR_
(Semmelweis University of Budapest, Budapest, Humgary)
Purpose: The impact of two different methods, i.e., resection and
reconstruction  versus  transfocal  internal  stabilization  of  bone
metastases was studied in 209 patients concerning the survival, life
quality and local complications.
Material and methods: Three hundred and thirty-eight  patients
with bone metastases were treated in two Institutions during the
period from 01/1990 to 01/2000. The minimum follow-up was
12  months. 129  patients  were excluded for  different  reasons.
One  hundred  and  nine  patients  (Group  I)  were  treated  with
complete resection of the metastasis followed by reconstruction
(endoprotheses  in  58  patients,  bone  grafts  in  two  patients,
blading and bone cement in 37 patients, resection  only in 12
patients) and 100 patients (Group II) with internal transfocal
stabilization (curettage, bone cement and blading; intramedul-
lary (interlocking-, Gamma-  or Ender-nailing) fixation and/or
bone  cementing.  The  patients  of  the  two  differently  treated
groups  were  matched  according  the  general  condition
(Karnofsky),  site  of  the  primary  tumor  (lung, breast,  kidney,
prostate and others). For the statistical analysis Fisher’s exact-
test,  the  t-test,  the  Kaplan–Meier  survival  curve  and  the
Cox–Mantel test were used.
Results: The survival differed significantly  in the two groups: in
Group I 46.6%, 1-year, 20.5%, 2-year, 10.7%, 3-year and 2.6%,
5-year survival rates were detected; versus 15.1%, 1-year, 4.04%,
2-year and 0% 3-year survival rates in Group II. Concerning the
site of the primary tumors the mean survival in kidney metastases
(17 months) was superior to the breast (11.3 months) and lung
(6.7 months) metastases. 
Conclusions:  The  type  of  surgery  does  not  influence  the  final
outcome of the disease. Resection and reconstruction is recom-
mended in the early stage (solitary form) and translocal internal
stabilisation in the more advenced stage (multiple form) of bony
metastases. At  correct indication, the rate of complications is
low (group I, 8% and group II, 11%) and comparable in both
groups. 
Treatment options in spine metastases of renal cell carci-
noma
A. GASBARRINI, S. BANDIERA, M. CAPPUCCIO, G. BAR-
BANTI, F. DE IURE, G. PIZZA & S. BORIANI
(Department of Orthopedics and Traumatology. Istituti Ortopedici Riz-
zoli, Bologna, Italy)
Aim: Evaluation of the different surgical options (simple decom-
pression  and stabilization versus intralesional  excision  versus en
bloc resection) in the treatment of spinal metastases from renal cell
carcinoma (RCC). 
Methods: Fifty cases in 44 patients with symptomatic spine metas-
tases secondary to RCC were reviewed between 1974 and 2000.
Eleven patients were submitted to radiation therapy only. In 16
cases a palliative procedure was adopted, in 18 cases a curettage
and in five cases an en bloc resection (two were marginal while three
were  wide). Seventeen cases  were operated on  for neurological
dysfunction, 27 for progressive pain. Radiation therapy (RTR) was
performed after the surgical procedure in 32 cases, preoperative
selective arterial embolization (SAE) in 11 cases, chemotherapy in
five cases and immunotherapy (IL2) in 14 cases.
Results: All cases were followed for at least 6 months (6–69 months;
average 15.3). The local recurrence percentage was none out of
three when it was done with a wide margin. The mean survival was
5.8 months (min. 2; max. 14) in the 11 patients who were treated
only  with  RTR,  13.5  months  (min.  10;  max.  16)  in  patients
submitted  to  palliative  surgery  (six  out  of  16  died)  and  29.8
months (min. 14; max. 69) in patients submitted to curettage (five
out of 18 died). Of the five patients operated with en bloc resection
only one died after 6 months.
Conclusions: The treatment of spine metastases of RCC is multidis-
ciplinary: the eligibility of patient to en bloc resection both on the
basis of general conditions and local tumor expansion is critical for
the local control of the disease. If en bloc resection is not feasible, a
combination  of  SAE,  complete  extracapsular  intralesional  exci-
sion, RTR and immunotherapy seems to be the most appropriate
treatment.
Life  expectancy  and  surgery  or  radiotherapy  for  spinal
metastases: proposal based on a surgical experience
C. VILLAS
(Department  of  Orthopaedics.  University  of  Navarra,  Pamplona,
Spain)
Introduction: Therapeutic decision making for patients with spinal
metastases is difficult because of the influence that many factors
have  on  results  and  risks  of  surgical  treatment.  Among  these
possible influencing factors, life expectancy may theoretically be a
good one when trying to establish an algorithm. Nevertheless, in
daily  practice,  we  often  miscalculate  life  expectancy  in  many
patients. Although radiotherapy may bring effective improvement
of pain and neurological impairment, it usually needs several days
or weeks and frequently closes the door for future surgery. When
spinal cord compression with neurological impairment exists, a few
days  of  delaying  decompression  may  be  crucial  for  patient’s
recovery chance.
Patients and methods: From 1979 to1995 we have operated on 121
patients  complaining  of  untreatable  pain  and/or  spinal  cord
compression. Evaluation included symptoms relief and patients’
survival.
Results: Even patients  with  short  life  expectancy  benefited  from
surgery  which  proved to  be  very  effective  in  relieving  pain  and
improving neurological function. Sixty-one patients received chem-
otherapy and/or radiotherapy before surgery with  no satisfactory
improvement of their complaints. Only 18 out of the 106 patients
with untreatable pain remained in a drug-dependent situation after
surgery;  five  morphine-dependent  patients  referred  no  improve-
ment after surgery. Seventy-three (80%) out of the 91 patients withAbstracts 233
neurological impairment in our series were unable to walk before
surgery, and only 22 were not able to walk after surgery (76% of
recovery). Survival was longer than one year in 22% of the patients.
Discussion: For patients  with  short  life  expectancy, radiotherapy
may reasonably be the first therapeutic step when the patient has
been informed and is aware of (and accepts) the risk of suffering a
possible  paraplegia.  In  deciding  treatment,  it  is  important  to
remember that time is  relative  and what may seem like a short
period of time from the doctors perspective, may seem an eternity
for a suffering patient.
Session 6: Free papers
Axial osteosarcoma: local surgical control is still of para-
mount importance in the age of interdisciplinary therapy
S. FLEGE, M. KEVRIC, V. EWERBECK, U. EXNER, U. HE-
ISE, A. HILLMANN, H. JÜRGENS, R. KOTZ, R. WINDHAG-
ER,  W.  WINKELMANN  &  S.  BIELACK  (FOR  THE
COOPERATIVE OSTEOSARCOMA STUDY GROUP COSS)
(Department of Pediatric Hematology/Oncology, University of Muen-
ster, Muenster, Germany)
Aim: Osteosarcoma of the trunk is rare. We set out to delineate the
role of surgery in this setting by evaluating a comparatively large
cohort of patients with localized axial disease.
Patients and methods: All patients with previously untreated (except
primary surgery) high-grade osteosarcoma of the axial skeleton regis-
tered into a neoadjuvant COSS study before seven of 98 were evalu-
ated for local control and survival. All protocols called for intensive
polychemotherapy and — whenever feasible — complete surgery.
Results: Eighty-five patients with localized axial osteosarcoma were
identified (49 male, 36 female; median age 19 years (range 5–62);
73  osteosarcoma  as  a  primary,  12  as  a  secondary malignancy;
tumor sites: pelvis 61, rib 10, spine seven, scapula five, clavicle
two). After a median follow-up MFU of 2.0 years for all patients
and 3.1 years (0.03–17.4) for survivors, 43 patients were still alive,
for an actuarial 5-year survival rate (5 yr OS) of 40%. Fifty-three
patients  (62%)  achieved  a  macroscopically  complete  surgical
remission.  Thirty  of  these  survived  (5  yr  OS  53%).  Forty-one
achieved permanent local surgical control (48% of all 85 patients
and  77%  of  the  53  who  achieved  a  local  surgical  remission).
Twenty-nine of the 41 survived (MFU 5.3 years, 5 yr OS 70%). By
comparison, 5 yr OS was only 4% for 42 patients without perma-
nent local surgical control, with only one patient alive past 5 years
(two  patients  without  sufficient  information  on  local  disease
status).
Conclusion:  Patients  with  localized  axial  osteosarcoma in whom
permanent local control can be established may enjoy an outcome
similar to that of patients with limb tumors. There is a dire need
for alternative strategies for those who fail locally.
Supported by Deutsche Krebshilfe
A  comparison  between  sporadic  and  neurofibromatosis-
associated malignant peripheral nerve-sheath tumours
V. PRASAD1, D.E. PORTER1, R. BIRCHE2, R.J. GRIMER1,
S.R. CARTER1 & R.M. TILLMAN1
(1Royal Orthopaedic Hospital Oncology Service, Woodlands, Birming-
ham; 2Peripheral Nerve Injury Unit, Royal National Orthopaedic Hos-
pital, Stanmore, London, UK)
Introduction:  Malignant  peripheral  nerve  sheath  tumours
(MPNSTs) constitute 10% of soft tissue sarcomas. A significant
proportion arise in neurofibromatosis type 1 (NF1). Several publi-
cations  have  compared  MPNST survival  in  sporadic  and  NF1
patients, without consensus on whether NF1 is an independent
factor for poor prognosis.
Methods: Clinical and histological data from 135 proven MPNSTs
were analysed from two national centres  for soft  tissue  tumour
surgery diagnosed from 1979 to 2000. One hundred and twenty-
nine  patients  had  follow-up  data  from  6  months  to  21  years.
Thirty-five were from patients with NF1. Local treatment involved
surgery in surgery in 95%, radiotherapy in 44% and chemotherapy
in 21%. 
Results:  NF1  patients  were  younger  than  those  with  sporadic
tumours (median age 26 vs. 53 years, P<0.001). Overall MPNST
survival was almost identical to that in soft tissue sarcomas as a
whole, but was worse in NF1 than in sporadic tumours (33 vs.
72% at 30 months (P<0.01), 17 vs. 39% at 60 months, 6 vs. 21%
at 120 months). A trend towards shorter time to local recurrence
was seen in NF1, but not time to metastasis. Superficial tumours
gave improved prognosis. Tumour volume over 100 ml was asso-
ciated with worse survival (46 vs. 91% at 30 months, P<0.02), as
was histological grade (80% high grade vs. 25% low grade at 60
months,  P<0.01).  In  terms  of  location,  a  non-significant  over-
representation of NF1 MPNSTs in the sciatic and brachial plexii
was identified.
Discussion: NF1 and sporadic MPNSTs exhibited no difference in
depth or tumour volume profile, although NF1 tended towards
higher  grade.  Analysis  of  survival  in  only  high-grade  tumours,
however, still resulted in a significant survival disadvantage in NF1
(33  vs.  70%  at 30  months,  P<0.01).  Removal  or brachial  and
sciatic  plexus  tumours from analysis did not affect survivorship
profiles in NF1 and sporadic MPNSTs.
Conclusions:  Grade,  volume  and  tumour  depth  correlate  with
survival; only seven of 45 patients with deep high-grade tumours
over  100  ml  volume  were  observed to survive beyond 2  years.
MPNST survival is worse in NF1 than sporadic tumours. Grade,
depth, site and volume differences could not explain this disadvan-
tage.
Extra-abdominal  desmoid  tumor:  a  new  treatment
modality including interferon-alpha and tretinoin
A. LEITHNER, R. WINDHAGER, B. SCHNACK, T.  KAT-
TERSCHAFKA, C. WILTSCHKE, G. AMANN, R. KOTZ &
C.C. ZIELINSKI
(Karl Franzens University of Graz, Graz, Austria)
Aim of the study: The postsurgical treatment of extra-abdominal
desmoid tumors (also called aggressive fibromatosis) is uncertain.
Therefore, a retrospective study was undertaken, to evaluate the
authors experiences with a new treatment regime including inter-
feron- (IFN-±tretinoin.
Methods: Thirteen patients with extra-abdominal desmoid tumors
and a median age of 32 years (range 15–73) received IFN-± and
tretinoin in order to prevent recurrence or to stabilize progressive
disease.
Results:  After  a  mean  observation  period  of  27±15  months
(mean±standard  deviation)  under  treatment  with  IFN-±,  local
control was seen in 11 of 13 patients (85%). Seven patients had no234 Abstracts
evidence  of  disease  at  a  mean  disease-free  interval  of  22±18
months; in two patients progressive disease occurred after only 7
and  9  months,  respectively,  of  observation.  In  another  four
patients, progression of the desmoid tumor was stabilized.
Conclusions:  A  literature  review  and  data  of  this  retrospective,
nonrandomized study on therapy with IFN-±tretinoin suggest that
such  treatment  may  be  affective  in  prolonging  the  disease-free
interval or to stabilize progressive disease. This regimen should be
considered as another nonsurgical treatment alternative.
Neoadjuvant  chemotherapy  for  non-metastatic  osteosar-
coma of the extremity: results of the protocol IOR/OS-4
S.  FERRARI,  M.  MERCURI,  F.  BERTONI,  P.  PICCI,  A.
LONGHI, M. MANFRINI, R. CAPANNA*, A. TIENGHI°, A.
BRACH DEL PREVER+, A. COMANDONE# & G. BACCI
Dipartimento di Oncologia Muscolo-Scheletica Istituto Ortopedico Riz-
zoli; * C.T.O. Firenze; ** Oncologia Medica Ravenna; *** Clinica
Pediatrica  Università  di  Torino;  ****  Oncologia  Medica  Ospedale
Gradenigo Torino. ITALY. 
Our previous experiences (Bacci, 1993) had shown that patients
with  nonmetastatic  osteosarcoma  having  a  poor  histological
response to a primary chemotherapy with methotrexate (MTX),
cisplatin (CDP), and doxorubicin (ADM) could benefit from the
addition of ifosfamide (IFO) in the postoperative phase of treat-
ment.  From  January 1993  to  July  1995  a neoadjuvant  chemo-
therapy protocol (IOR/OS-4 ) based on the preoperative use of
IFO in all patients, added to CDP, ADM and MTX was carried
out at our institution. Primary chemotherapy consisted of MTX 12
g/m2 (weeks 0–4), CDP (120 mg/m2) plus ADM (60 mg/m2) on
week 1, IFO (6 g/m2) plus CDP (120 mg/m2) on week 5, and IFO
(6  g/m2)  plus  ADM  (60  mg/m2)  on  week  8.  Postoperatively,
patients received MTX 12 g/m2 (weeks 15, 24, 33, 42), ADM 90
mg/m2 (weeks 11, 21, 30, 39), CDP 120 mg/m2 (weeks 16, 25,
34), and IFO 10 g/m2 (weeks 19, 28, 37). One hundred and thirty-
three patients (median age 16, 3–40) with non-metastatic osteosa-
rcoma of the extremity entered the study. Two patients died during
the  preoperative  phase  (one  suicide,  one  toxic  death).  One
hundred and thirty-one patients underwent surgery: limb salvage
surgery  in  123  (94%)  patients;  three  rotationplasties,  and  five
amputations. During the postoperative phase two chemotherapy-
related deaths were registered (acute renal failure, and veno-occlu-
sive  disease).  With  a  median  follow  up  of  6  years,  75  (56%)
patients were event-free; 54 (41%) relapsed with distant (44, 33%)
or local (10, 7.5%) recurrence. Of the 54 patients who relapsed, 12
(22%) were NED II, four (7.5%) were AWD, and 38 (70.5%) died
of disease. The 7-year cumulative probability of EFS and OS were
56% (95% CI 48–65), and 69% (95% CI 59–78), respectively. In
the previous Rizzoli study (IOR/OS-3) based on the use of IFO
only in poor responder patients, the 7-year EFS and OS were 54%
(95% CI 44–64) and 61% (95% CI 51–71), respectively; the local
recurrence rate was 3%. In non-metastatic  osteosarcoma of the
extremity, the use of MTX, CDP, ADM and IFO since the preop-
erative phase does not seem to offer advantages compared to the
use of MTX, CDP and ADM with IFO delivered in the postoper-
ative phase and in poor responder patients only. 
Urinary excretion of pyridinium crosslinks in patients with
osteosarcoma
S. FERRARI, C. ZOLEZZI, M.C. FASANO, L. PRATELLI L &
G. BACCI
(Dipartimento di Oncologia Muscolo-Scheletrica, Laboratorio Analisi,
Istituto Ortopedico Rizzoli, Bologna, Italy) 
Pyridinium  crosslinks  (Pyr,  D-Pyr), are  molecules  of collagenic
origin  currently  considered  markers  for  the  diagnosis  of  bone
metastases.  Disturbances  in  bone  remodelling  in  patients  with
primary bone tumors have been little investigated. The aim of the
present study was to investigate the urinary excretion of Pyr, D -
Pyr, alkaline phosphatase (AP) and and serum osteocalcin (OC),
in patients with osteosarcoma of the extremity. Thirty-six patients
(median age 14 years, 7–22) with osteosarcoma of the extremity
(six metastatic at presentation) entered the study. A control popu-
lation of age- and sex-mached  healthy  individuals  was  studied.
Urinary excretion of Pyr, D -Pyr were measured on fasting urine
specimens, corrected for creatine excretion (Ucr), and expressed
as  pM/µM  UCr.  At  the  same  time  of  urine  collection,  blood
samples were taken for measurement of AP, and OC.  The urinary
excretion of Pyr and D -Pyr were significantly (P 0.005, P 0.003)
higher in patients with osteosarcoma (481.5±346, 82.7±59) than
in control population (231±134, 38.2 ± 22.5). No differences were
found according to the osteosarcoma histological subtypes, or to
the presence of metastases. Tumor volume did not correlate with
urinary excretion of Pyr and D-Pyr. A significantly higher excretion
of Pyr (P=0.057) and D-Pyr (P=0.02) was found in patients who
relapsed (Pyr 578.1±374,  D-Pyr 96.8±65.3) compared to those
who remained continuously free of disease (Pyr 304.5±134, D-Pyr
58.1±22).  A  highly  significant  correlation  was  found  with  AP,
whereas no correlation was found with OC. The serum level of OC
was significantly (P 0.0001) lower in patients with osteosarcoma
(4.8±5.3 ng/ml) than in control population (20.3±7.6 ng/ml). The
present  study  showed  significant  abnormalities  of  the  urinary
excretion of pyridinium crosslinks in osteosarcoma patients. Their
possible use to monitor treatment can be proposed. The possible
relation  between  baseline  urinary  excretion  of  pyridinium
crosslinks  and  biological  tumor  aggressiveness  observed  in  the
present study require further investigations. 
Rehabilitation after surgery of tumors of the foot
AXEL  HILLMANN1,  CAROLA  BERTSCH1,  GEORG
GOSHEGER1,  DIETER  ROSENBAUM2  &  WINFRIED
WINKELMANN1
(1Orthopaedic Department,  2Movement Analysis  Lab,  University of
Muenster, Muenster, Germany)
Introduction:  Primary  malignant  tumors  of  the  foot  are  rare.
Complete resection is recommendable according to the Enneking
classification. When the tumor is destructive an invasive amputa-
tion  is  required  in  many  cases.  In  primary  bone  or  soft  tissue
tumors a partial resection of the foot is possible, when the tumor
shows a good response to adjuvant chemotherapy and radiation. In
the present study the functional outcome has been evaluated by
plantar pressure measurements.
Material and  Methods: Six patients  with a high  grade malignant
tumor of the  foot (2nd metatarsal,  n=3; 4th and 5th  ray, n=1;
Syme amputation, n=1) were clinically and functionally examined.
Plantar pressure measurements  were taken for barefoot walking
and inside the shoe with capacitive pressure distribution platform
and insoles (EMED & PEDAR, Novel, Munich). Several steps
during full  gait  were selected  and averaged to present  a typical
loading  pattern.  Foot  loading  parameters  were  determined  for
different regions of the foot and compared with the contralateral
side.
Results: Walking ability  depended in general on the  degree and
location of the resection. The patients with resection of the 2nd ray
showed an increased loading of the midfoot and fore foot with
decreased load under the toes. Both of them had a good foot func-
tion with high mobility. The patient with a resection of 4th and 5th
ray had a decreased area and force under midfoot and forefoot,
with a decrease in peak pressure under the toes as well. Peak pres-
sure under the forefoot, however, increased clearly. A resection of
the calcaneus led to decreased loads under the fore foot, hallux andAbstracts 235
toes. An amputation in the Chopart joint line was associated with
an almost similar loading situation of the stump compared with the
contralateral hind foot. Wearing an individual forefoot prosthesis
led to increased loading of the stump.
Discussion: The foot loading parameters change after partial resec-
tion of the foot due to a primary bone tumor. In the case of ray
resection good functional results and loading parameters similar to
a normal foot can be observed. In shoe pressure measurements are
a valuable tool to evaluate the effect of orthotics.
Treatment  of aneurysmal bone cyst  by direct injection of
ethibloc in children
E. MASCARD, C. ADAMSBAUM, G. KALIFA & J. DUBOUS-
SET
(Pediatric Surgery and Radiology Departments, Hospital Saint-Vincent
de Paul, Paris, France)
Aneurysmal  bone  cysts  (ABC)  are  benign  but  sometimes  very
aggressive lesions. The accepted treatments are aggressive bone
curettage  or  marginal  resection.  Ethibloc  is  a  fibrogenic  and
thrombogenic agent used for vascular embolisation. Our purpose
was to report the results of treatment of ABC by Ethibloc. From
1991 to 2000, 16 patients with aneurysmal bone cyst were treated
by direct injection of Ethibloc. There were 12 females and four
males, aged 2–14 years (mean 8 years). The diagnosis was always
assessed by open biopsy. Six patients had various previous surgical
treatments.  Locations  of  the  lesions  were  the  proximal  femur
(four), the proximal humerus (three), the acetabulum (two), the
clavicle (two), the distal fibula (two), the distal humerus (one), the
distal ulna (one), and the second metacarpal (one). All injections
were performed under general anesthesia, with control by image
intensifier or CT scan. Before Ethibloc injection, opacification of
the  cyst  was achieved by contrast medium  to look for vascular
drainage.  Results  were  retrospectively  assessed  at  3-year  mean
follow-up (6 months to 7 years). Immediate complications were
three cutaneous fistulae that healed spontaneously, in which one
underwent  a  scar  excision  for  cosmetic  reasons.  Most  of  the
patients developed fever and inflammatory local reaction after the
injection. There was no deep infection, no pulmonary embolism,
and no malignant degeneration. In two cases, the injection had no
effect on the ABC, requiring surgical excision, and in one case the
remaining  cyst  had  to  be  curetted.  All  other  13  patients  had
complete healing or ossification of the ABC. In conclusion, direct
Ethibloc injection is a minimally aggressive but effective treatment
of ABC. Because of the possible intense inflammatory reaction, we
do not recommend that treatment in spinal or distal (hand and
foot) lesions.
Giant cell tumour of bone in the elderly
V. PRASAD, D.E. PORTER, N. EVANS, R.J. GRIMER, S.R.
CARTER & R.M. TILLMAN
(Royal Orthopaedic Hospital Oncology Service, Birmingham, UK)
Introduction and aims: Giant cell tumour of bone (GCT) occurs in
a characteristic age distribution, approximately 75% arising in the
third and fourth decades of life, the incidence diminishing rapidly
thereafter. In fact, a literature review encompassing 473  GCTs
records only eight cases diagnosed beyond age 70. Although GCT
characteristics are described in the skeletally immature, no detailed
analysis has been undertaken in the elderly, which was the purpose
of this study. 
Methods  and  results:  From  1981  to  2000,  334  histologically
confirmed primary GCTs were treated in our Unit. Five presented
in patients over age 70, including, perhaps, the oldest recorded in
the literature. All were referred from other hospitals, four with a
provisional clinical diagnosis of metastatic bone disease, probably
because of their age. 
Clinical  and  radiographic  review  classified  two  cases  as  active
benign GCTs at typical sites, two as active aggressive GCTs at
atypical sites, and one with intermediate features. Investigations
(including biopsy) and treatment options were identical to those in
younger patients,  and successful,  although  one  patient  died  of
lobar pneumonia prior to surgery.
Discussion and conclusions: GCTs do occur in the elderly (although
perhaps not beyond age 80). Biopsy is mandatory to exclude meta-
static or primary malignant bone disease. Treatment as for younger
patients is successful. 
Chondroblastoma of bone
R. SUNEJA, M. BELTHUR, N. DESHMUKH, R.J. GRIMER,
S. CARTER & R.M. TILLMAN
(Royal Orthopaedic Hospital Oncology Service, Birmingham, UK)
Introduction: Chondroblastoma is generally accepted as a benign
neoplasm,  which  largely  manifests  in  adolescence  during  the
period of active epiphyseal plate growth. The treatment modalities
for this  condition are quite variable and the rates of recurrence
following them controversial.
Aims: This study was carried out with the aim to evaluate the rates
of recurrence following the intralesional curettage technique and
evaluate the functional outcome objectively using the Enneking’s
functional evaluation scoring system. We have also attempted to
define factors associated with more aggressive tumour behaviour.
Methods: This is a retrospective study of 70 patients with chond-
roblastoma treated over the past 27 years at our unit. The age at
presentation, sex, anatomical site, signs and symptoms, operative
procedure and post-operative complications were noted. The radi-
ographs were reviewed for the location and size of the lesion, the
amount  of  cortical  destruction  and  the  status  of  the  adjacent
epiphyseal  plate.  The  histopathology  slides  were  studied  with
special  emphasis  on the presence or absence of the  aneurysmal
bone component.
Results:  Out  of  the  70  patients  included  initially,  53  had  their
primary treatment procedure performed at our unit in the form of
an intra-lesional  curettage, and were followed-up of at least 22
months, up to a maximum of 27 years. There was a histologically
proven local recurrence in six out of these 53 cases (11.3%). Three
patients underwent a second intralesional curettage procedure and
had  no  further  recurrences.  Two  patients  had  endoprosthetic
replacement of the proximal humerus and one patient underwent
a below knee amputation following aggressive local recurrences.
One patient had the rare malignant metastatic chondroblastoma
and died eventually. We were able to perform an objective assess-
ment of the functional outcome in 40 patients (duration of follow-
up  22–324  months)  using  Enneking’s  functional  evaluation
scoring system. The mean score was 94.1%. 
Conclusion:  We conclude that  meticulous  intralesional curettage
without any additional procedure can achieve low rates of local
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An algorithm for diagnosing non-traumatic bony lesions of
the clavicle
S.R. CARTER, S. MAIYA, P.B. PYNSENT, R.J. GRIMER &
R.M. TILLMAN
(Royal Orthopaedic Hospital Oncology Service, Birmingham, UK)
Aim: To propose an algorithm for the diagnosis of bony lesions of
the clavicle
Introduction: Non-traumatic lesions of the clavicle include infec-
tion,  benign  and malignant  tumours  and certain  miscellaneous
bizarre  sclerotic  lesions.  The  diagnosis  of  these  conditions  has
traditionally  been  difficult  not  only  due  to  the  rarity  of  these
lesions, but also due to the large variety of conditions that affect the
bone and the problems encountered in imaging the clavicle.
Materials and Methods: We analysed over 102 patients with clavic-
ular lesions referred to our unit over a 30-year period and looked
at  the  case  histories,  investigation  methods,  diagnosis  and
outcome.  We  classified  the  lesions  into  four  useful  groups  for
clarity  in  analyses,  viz:  infections,  benign  tumours,  malignant
tumours and miscellaneous conditions.
Results: The distribution of lesions is similar to that seen in the
long bones with the two ends of the bones being affected the most
(67.4% in medial third and 21.9% in lateral third). Of the 102
cases, lesions were uniformly distributed with infection seen in
37(36.3%)  cases,  tumours  in  39  (38.2%)  and  miscellaneous
conditions seen in 26 (25.5%) of the patients. Infection was more
commonly seen in the young and affected the medial third of the
clavicle  (94.6%).  Tumours  were  seen  in  an  older  group  and
predominantly  affected  the  lateral  third  (81%).  Infection  was
more  commonly  sclerotic  and  expansile  (77.1%),  whereas
tumours  were  lytic  and  destructive  (88.2%).  ESR,  CRP  and
other blood parameters were not very helpful. Bone scans were
useful only in detecting metastatic lesions and MRI scans were
needed to localize  these  lesions  and to pinpoint  a site  for  the
biopsy.  An  algorithm  is  presented  to  aid  in  the  diagnosis  of
lesions of the clavicle.
Conclusions: This study has confirmed the difficulty in making a
clinical and radiological diagnosis of lesions of the clavicle. Some
patterns in presentation in terms of age, location, X-ray appear-
ance and other imaging modalities are evident. But ultimately we
advocate a low threshold for biopsy of these lesions to allow diag-
nosis. 
Is fruit a useful indicator of the size of an object?
J.M. GRAY, M.T. KHAN, R.J. GRIMER & P.B. PYNSENT
(Royal Orthopaedic Hospital Oncology Service, Birmingham, UK)
Background: The use of inanimate objects is often used as a meta-
phor to describe the size or shape of pathological swellings, and it
is our experience that soft tissue tumours are particularly described
in this way (e.g., this lump is the size of a gape/apple/melon).
Aims and methods: This study aimed to assess the accuracy and
therefore validity of this descriptive practice by questionnaire to
orthopaedic  specialists.  Participants  were  asked  to  indicate  the
diameter of standard non-consumable items (tennis and golf balls)
and consumables (fruit and vegetables) and also to estimate the
size of a line drawing. Published sizes were found for objects. 
Results: Current EEC sizes of fruit and vegetables were variable,
most  indicating  only  a  minimum  size.  Golf  balls  also  have  a
minimum  standard and tennis  balls  a  choice of  standard sizes.
Eighty-three  questionnaires  were completed.  Estimated  sizes  of
these  objects  varied  widely.  Estimation  of  the  size  of  the  line
diagram was quite accurate. 
Conclusion: Using  fruit  to describe  the  size  of an object has no
validity. Not only are there no standard sizes for fruit but ortho-
paedic surgeons perceptions of size also vary widely. Although less
interesting in description the actual measurement of size should be
the norm. Every surgeon should carry a tape measure in his/her
pocket!
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C-ErbB-4 expression in limbs STS: correlation with neoad-
juvant chemotherapy results
O. MERIMSKY, J. ISSAKOV, J. BICKELS, Y. KOLLENDER,
G. FLUSSER, S. VJACHESLAV, I. SCHWARTZ, M. INBAR,
L. MELLER
(The Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel)
Purpose: ErbB-4 is a recently described member of the epidermal
growth factor receptor (EGFR) family. Relatively little is known
about the expression of erbB-4 in human tumors. In the present
study we assessed the possible role of c-erbB-4 expression product
as a tissue marker for STS, and its correlation with the response to
chemotherapy.
Patients: The histological specimen of 29 patients with STS of a
limb  who  had  received  preoperative doxorubicin-based  chemo-
therapy were studied. The extent of tumor necrosis was evaluated
histologically.  Paraffin  blocks  of  preoperative  incisional  biopsy
were available for immune staining (avidin-biotin-peroxidase tech-
nique) from 29 patients, and blocks of the surgical specimen after
pre-operative chemotherapy were available from 27.
Results: The objective response rate to preoperative chemotherapy
was 34%. Wide resection of the tumor was feasible in 12 patients,
marginal resection in 14 cases, amputation in 2 patients with disease
progression, and no surgery in one case. The tumor necrosis was
above 90% in 9 patients, 60–90% in 12, and less than 60% in 7
patients. It was found that an increase in C-erbB-4 expression was
more common in cases with no response to chemotherapy, while no
change of or decrease in C-erbB-4 was more common in responsive
tumors  (p=0.004).  No  correlation  could  be  found  between  the
degree of necrosis or the chemotherapeutic regimen and the change
in expression of c-erbB-4. The median DFS was longer for patients
with a decrease or no change in expression of C-erbB-4 than for
patients with increased expression.
Discussion: It is believed that post chemotherapy new expression or
no  down-regulation  of  the  erbB-4  molecule  represents  tumor
aggressiveness and increased capability of growth and spread.
Late complications after radiotherapy in ewing sarcoma
ORLI_ D, SMERDELJ M, KOLUNDZI_ R, ORLI_ IVNA*
(Department of Orthopaedic Surgery, School of Medicine, University of
Zagreb, Croatia)
Treatment of patients with Ewing’s sarcoma in the last period is
giving good results. Longer survival of patients has resulted some-
times  in  the  observation  of  some  late  complications  related  to
previous  treatment.  Our  experiences  with  two  patients  were
presented.Abstracts 237
Radiotherapy and chemotherapy in a boy aged 12,  in 1986  was
applied. A healing process of the tumor was achieved with irradia-
tion, but subsequently the extensive complications of applied irradi-
ation developed. A year after irradiation atrophy and hypotrophy of
the irradiated thigh, along with contracture of the hip joint and the
knee joint developed. The leg was totally atrophic, shorter by some
10 cm with nonunion of a pathological fracture in the middle third
of the femur. Amputation of the lower extremity because of quite
miserable quality of life and completely afunctional leg 4 years and
10  months  after  was  indicated.  Histological  examination  of  the
extremity did not show any signs of a tumor. In all layers of the
markedly atrophic tissue,  i.e. the skin, subcutaneous fatty tissue,
muscles and bone, signs of necrotic changes were presented with
extensive calcifications and formation of scar tissue. Minimal or very
slightly marked tissue regeneration was registered, while the osteob-
lasts were very faintly active. Similar changes were present in the
blood and lymph vessels, causing edema and congestion.
Identical  atrophic  changes  with  good  healing  in  early  stage  of
partial stress fracture in the middle third of the femur were regis-
tered 15  years after irradiation of Ewing sarcoma in the  young
women. Today she is normal working mother with two children
and excellent quality of life.
Late  complications  after  contemporary  radiotherapy  in  Ewing
sarcoma are not clinical problem any more.
Reimplantation  of  reirradiated  tumour  bone:  advantages
and pitfalls
KHAN M., GRIMER R., PEAK D
(Royal Orthopaedic Hospital Oncology Service. Birmingham, U.K)
Limb salvage surgery is now the preferred method of treatment for
malignant tumours of bone. It can be achieved by en-block resec-
tion of the bone followed b arthrodeses, endoprosthetic replace-
ment or allograft reconstruction of the defect.
We have re-implanted the patient’s bone for reconstruction of the
defect after debulking the tumour and irradiating the bone. This
method  was  used  in  ten  patients  with  aggressive  grade  IIB
sarcomas (osteosarcoma, Ewing’s sarcoma) of the pelvis, humerus,
tibia and metacarpal. Median overall survival of the patients was
24 months with a maximum survival of sixty-nine (69) months.
Four patients were alive at the most recent follow-up. One of them
is alive with metastatic disease and local recurrence while others
remain free of disease. One patient has had pathological fracture
through the irradiated bone that healed with conservative meas-
ures. One patient developed avascular necrosis of the femoral head
and required resurfacing arthroplasty of the hip.
The pelvic sarcomas continue to be a challenge. Resection, extra-
corporal irradiation and re-implantation may offer some hope but
it remains experimental. It should only be offered after a careful
review of  the  other  options for  reconstruction. It  is  technically
demanding and associated with a high incidence of complications.
Result of limb salvage surgery (498 sarcomas in 25 years)
DELEPINE  GÉRARD1, DELEPINE  FABRICE2, DELEPINE
NICOLE1
(1Oncologic Ped. Sce Hop. Avicenne Bobigny, 2Passage du bon pasteur,
Rouen, France)
Methods:  From  1/1975  to  31/12/200,  498  bone  sarcomas  were
treated by our multidisciplinary team. Average age of patients (p.):
27.1 years. Average size of the tumor (T): 13.1 cm. Histology: 231
osteosarcomas (OS), 118 chondrosarcomas, 104 Ewing (EW), 25
malignant  histiocytofibromas,  12  fibrosarcomas  and 8  miscella-
neous.  Locations:  femur  (203),  innominate  (98),  tibia  (86),
humerus  (60).  Staging:  III  in  64.  En-block  resection  was
performed by the same surgeon. Histology of margins showed wide
resection (295), marginal (185) and contaminated (18). Adjuvant
therapy was adapted to age of p., histology and location. Postoper-
ative RXT (35–50 grays) was administered in some adults with OS
and  EW,  whose  histological  response  to  neoadjuvant  chemo-
therapy (CT) was bad and resection marginal or contaminated.
Results:  With  a  median  FU  of  11  y.,  252  p.  are  alive  without
disease, 8 still receive treatment and 238 are dead from illness or
complications of treatment. 35 local recurrences occurred, most of
them (26) in p. who were referred after ineffective RXT or CT.
Complications: 42 deep infections, 24 p. secondarily amputated.
Functional results: At last FU, function excellent 52, good 35, fair
7%, poor 6%. It hanged mainly on size of T, could be altered by
complications (infection) or RXT.
Conclusion: 1) L.S. is feasible in more than 95%, even for huge or
fractured T. 2) The functional result is the best plae for L.S. 3)
Risk of local recurrence for first hand H.G. sarcoma is only 2%.
For low grade T or when no effective CT can be administered the
risk of local recurrence increases. 4) RXT can help in local control
for EW and mesenchymal chondrosarcoma but not significantly
for others. As most of secondary amputation, and most poor func-
tion have been observed in irradiated p. RXT must be avoided. 5)
What is the optimal timing for surgery? Preoperative CT is poten-
tially dangerous for p. when insufficiently effective CT is adminis-
tered  for  a  too  long  period.  In  our  practice,  1  month  of
preoperative CT for OS and 6 weeks for EW are enough to fulfil
the needs of CT and surgery.
Soft  tissue  reconstruction  of  megaprostheses  using  the
mutars® – trevira-tube
GEORG GOSHEGER*, AXEL HILLMANN*, HORST BÜRG-
ER**, WINFRIED WINKELMANN*
(Department of Orthopaedics* and Gerhard-Domagk-Institute of Pa-
thology** University of Münster, Germany)
In soft tissue reconstruction of megaprostheses the reattachment of
soft  tissue  and joint  capsules  is  essential.  Sixty-nine  megapros-
theses were implanted and a trevira tube was applied to support
reconstruction of the capsule and soft tissue. In the case of prox-
imal  femur  replacement  (33  patients),  total  femur  replacement
(five patients) and proximal humerus replacement (16 patients),
the trevira tube allows for reconstruction of the capsule and refix-
ation of the muscles and helps to minimize dislocation. In the case
of a proximal tibia replacement (seven patients), arthrodesis of the
knee (three patients), total knee replacement (two patients) and
distal femur replacement (three patients), the trevira tube allows
for attachment of muscle flaps and extensor tendons. Dislocation
was observed in two of 54 patients only, who had proximal femur
replacements. No dislocation was observed in patients with a total
femur  endoprosthesis  or  a  proximal  humerus  endoprosthesis.
Furthermore the trevira tube was used to attach the gastrocnemius
muscle in patients with a proximal tibia endoprosthesis and to reat-
tach the rotator cuff in patients with a proximal humerus pros-
thesis. In addition there was no significant increase in the rate of
infection (p = 0.46; chi square test). The histopathologic findings
in six patients showed a tissue ingrowth into the tube.
Osteoid  osteoma  and  osteoblastoma of the  spine:  experi-
ences of 22 patients
TOSHIFUMI  OZAKI,1  ULF  LILJENQVIST,1  AXEL  HILL-
MANN,1 HENRY HALM,2 NORBERT LINDNER,1 GEORG
GOSHAGER,1 AND WINFRIED WINKELMANN1
(Department of Orthopaedics, Westfälische Wilhelms-University, Mün-
ster and 2 Department of Spine Surgery, Klinikum Neustadt, Neustadt,
Germany)238 Abstracts
Osteoblastomas and osteoid osteomas of the spine are relatively
rare bone forming tumors.
Between 1980 and 1999, nine patients with osteoid osteoma and
13  patients  with  osteoblastoma had surgical  treatment  for their
tumors. Four tumors were in the cervical spine, six tumors were in
thoracic  spine,  10  tumors  were  in  the  lumbar  spine,  and  two
tumors were in the sacrum.
The average duration between onset of pain and surgery was 16.6
months in 12 patients treated in the 1980s and 8.6 months in 10
patients treated in the 1990s. Seventeen patients had scoliosis. In
nine of 10 patients with magnetic resonance imaging scans, high
signal intensity areas in the muscles and bone around the lesion
were seen. Two of nine patients with osteoid osteoma and nine of
13  patients  with osteoblastoma  had neurologic disorders before
treatment.  All  patients  had  open  resection  of  the  lesions.  Two
patients with osteoid osteoma had relapse because of incomplete
resection, necessitating a second excision. In 16 of 17 patients with
preoperative spinal deformity because of inflammatory effect of the
lesion, the deformity improved during followup.
With development of modern imaging techniques, exact surgical
planning may become possible; however, in some cases, intraoper-
ative complete resection of the lesion is still difficult.
Clinical outcome in treatment of parosteal osteosarcoma
A.H.M.  TAMINIAU,  P.D.S.  DIJKSTRA,  H.M.  KROON,
P.C.W. HOGENDOORN
(Dep. orthopedic surgery, dep. radiology, dep. pathology. Leiden Uni-
versity Medical Centre, Leiden, The Netherlands)
Seventeen patients with a parosteal (juxtacortical) osteosarcoma
treated  between  1980  and 1998  at  Leiden  University  Medical
Center were reviewed. The clinicopathological features, diagnosis,
surgical treatment, and patient outcome were analysed.
The median age of patients was 35 years, range 13 to 61 years. The
distal part of the femur was the most common site (9 patients). The
other lesions were located at the proximal femur in 4 patients, at the
tibia in 1 patient, at the humerus in 2 patients, and at the radius in
1  patient.  A  dedifferentiated  component  was  identified  in  one
patient. A wide, marginal and positive surgical margin were found in
9, 4 and 4 patients, respectively. Three patients had a local recur-
rence treated successfully with further surgery. Surgical staging for
stage IA, IB, IIB resulted in 9, 5 and 3 patients, respectively. The
different types of reconstruction after resection of the lesion were: an
inlay graft in 9 patients, intercalair graft in 3 patients, osteoarticular
graft in 3 patients, transposition of the bone in one patient, and no
additional reconstruction in one patient. In one third of the patients
a  local  complication  established,  and  no  systemic  complications
occurred.  Failure  of  reconstruction  developed  in  7  patients,  of
whom  4  patients  with  a  non-union needed a  re-operation.  The
median functional outcome score (MTSS) for the upper extremity
was  24  and for  the  lower  extremity  27.5.  Radiological  implants
system evaluation (ISOLS) for implant and allograft was found to be
excellent to good in 11 patients one year after surgery. One of the
patients died of the disease (stage IIB) 11 years after surgery. The
median follow-up was 6.5 years (range 2.5 to 14.5 years).
Despite  failure  of  reconstructions  the  functional  outcome  was
good, and the prognosis was excellent.
Endoprosthesis for metastases to proximal femur
KHAN M., TILLMANN R., GRIMER R., CARTER S
(Royal Orthopaedic Hospital Oncology Service. Birmingham, U.K)
The management of patients with metastatic disease of bone has
improved due to advances in chemotherapy and new surgical tech-
niques. The patients are now expected to live longer and demand
a better function and improved control of their symptoms.
Metastases to proximal femur are difficult to manage with standard
techniques  of  osteosynthesis  as  the  union may  be  delayed  and
implant may fail before fracture healing. Conventional prosthetic
replacement has been tried but they are usually associated with
problems.
We  have  used  endoprosthetic  replacement  in  sixty-two  (62)
patients with metastases in proximal femur. The mean age of the
patients was 56.7 years ranging from 33–84 years. All patients were
followed up till death or failure of the implant. The commonest
primary  tumours  were  carcinoma  of  breast  or  kidney.  Overall
survival  at twelve months  was  68.8%  and 27.8%  at forty-eight
months. All  patients  reported  an improvement  in  mobility  and
reduced requirement of analgesia after the endoprosthetic replace-
ment.  Dislocation  of  the  prosthesis  at  the  hip  joint  was  the
commonest occurring complication. Wound infection was seen in
three patients.
We believe that endoprosthetic replacement of the proximal femur
offer a successful method of stable reconstruction after resection of
the tumour. It has a low incidence of complications and improves
the quality of life by reducing pain and facilitating independent
mobility.
Treatment of pathologic proximal femur fractures
F.  PORTABELLA,  M.  ORDUÑA,  J.  CASAÑAS,  D.  ROD-
RIGUEZ
(Orthopaedics  Department,  Ciutat  Sanitaria  Bellvitge.  Barcelona,
Spain)
Introduction:  Neoplastic  disease  treatment  by  chemotherapy,
hormone therapy and radiotherapy has increase the survival of the
patients, so bone metastasis has increased. Frequently pathologic
proximal fractures femur is a complication in patients outcome.
Material and methods: 90 fractures has been surgically treated in the
last 7 years. The localization were: head and neck (42) and meta-
physis (48). The surgical technique include internal fixation (ender
nail 14, screw-plate 4 and screw-plate with cement 12) or arthro-
plasty reconstruction (Austin Moore 10, Wagner 9, bipolar pros-
thesis 16, Charnley 8 and Modular prosthesis 17).
Results: Recovery extremity function and pain relief was accom-
plished and functional results by treatment were as follows: ender
nail  4  good  and  8  poor,  screw-plate  4  poor,  screw-plate  with
cement 8 good and 4 poor, arthroplasties 56 good and 6 poor.
The complications were: failure implant 16, infection 3 and pros-
thesis dislocation 6.
Conclusions: Patients with life expectancy more than two months
would benefit with surgical treatment. Bone reconstruction with
intramedullary nail or screw-plate  has been shown to be inade-
quate  at  long  term  because  exist  a  high  incidence  of  failure.
Internal  fixation  augmented  with  methylmetacrylate  to  fill  the
defect and restore the medial cortex has achieved better results.
When the tumour extend towards the lesser trochanter we recom-
mended resection and reconstruction with modular prosthesis and
when the acetabulum is not involved we tend to use bipolar cups
because of their more stability.
Failure osteosynthesis in the treatment of pathologic inter-
trochanteric fractures
F. PORTABELLA, M. ORDUÑA, J. CASAÑAS, J. ARMENGOL
(Orthopaedics  Department.  Ciutat  Sanitaria  Bellvitge.  Barcelona,
Spain)
Introduction: The aim of the study is to evaluate the failure osteo-
synthesis in the treatment of pathologic intertrochanteric fractures.Abstracts 239
Material and methods: 56 intertrochanteric fractures has been surgi-
cally treated in the last 5 years and we find 20 cases of failure oste-
osynthesis (13 ender nail, 6 screw-plate, 1 gamma nail). In all the
cases the elected surgical procedure was based on the life expect-
ancy estimated by the oncologist.
Results: In all the cases had lost of fracture reduction with proximal
or distal migration intramedullary nails or the osteosynthesis mate-
rial became broken. The reasons of failure was the further progres-
sion of  metastatic  disease. The  treatment  performed were new
introduction of nails, arthroplasty joint replacement and medical
treatment against pain as needed without other surgical procedure
attending the general medical status of this patients.
Discussion:  The  specific  plan  to  treat  the  pathological  intertro-
chanteric fractures has to take in account several factors: expected
survival, type and stage of the tumour, visceral spread, the kind and
the extension of bone lesion, etc. One of the more important factor
is the life expectancy but in some cases is difficult to precise the
survival time, and the surgeon not consider the kind and extension
of lesion. The survival of this patients we got failures in the fixation
procedures especially when the medial cortex of the femur is not
restored. In conclusion we recommend joint replacement by using
modular prosthesis  in treating intertrochanteric pathologic frac-
tures with large bone destruction affecting patients with an esti-
mated life expectancy higher than six weeks.
Neo-adjuvant therapy plus conservative surgery in wide soft
tissues sarcoma of proximal extremities
R. CAPANNA, G. BELTRAMI, D.A. CAMPANACCI, M. MUG-
NAINI, P. DE BIASE, P. OLMIº, M. MELAº, M. PERTICIº
(Department of Orthopedic Oncology, C.T.O., Firenze º Department of
Radiotherapy, Firenze, Italy)
In  order  to  achieve  a  conservative  surgery  in  wide  Soft  Tissues
Sarcoma  (STS)  of  proximal  extremities,  neo-adjuvant  External
Beam  Radiation  Therapy  (EBRT)  associated  to  Chemotherapy
(CHT) have been introduced in Our Department. We report the
experience of six patients, treated from 1998 to 2000, all affected by
high grade STS, all with a diameter more than 10 cm. Upper limb
(axilla and deltoid region) was involved in two cases and lower (quad-
riceps or posterior thigh) in four cases. All patients were treated by
preoperative chemotherapy (Epirubicin + Ifosfamide, av. 2.5 cycles)
plus EBRT (av. 45 GY). After neo-adjuvant treatment, all patients
were operated by limb sparing surgery. Wide surgical margins were
achieved in all cases. Free flaps (motor unit transfer of innervated
latissimus  dorsi pro quadriceps) were employed in 2  cases, while
rotational flaps were used in one case (motor unit transfer of inner-
vated  latissimus  dorsi  pro  deltoid).  After  surgery,  one  deep
hematoma and one scar slough were observed, surgically repaired.
The necrosis, evaluated in the specimens, was excellent in 1 case
(100%), good (>90%) in 4 cases and poor in 1 (40%). Adjuvant
chemotherapy  (Epirubicin  +  Ifosfamide,  av.  2.5  cycles)  was
employed in all but one cases, while no adjuvant radiation therapy
was employed. At an average follow up of 15 months, five patients
were continuous disease free, and one patient is alive with multiple
pulmonary metastasis. Functional results (according to MSTS) were
rated as satisfactory in all cases. In locally advanced STS, neo-adju-
vant therapy showed to be efficacy in achieving limb-sparing surgery,
by tumoral mass shrinking of proximal extremities. In case of a motor
unit transfer, preoperative EBRT is strictly recommended, to avoid
damages caused by postoperative EBRT on flaps viability.
Periosteal Ewing’s sarcoma (PES). report of four new cases
F. DELPINE2, N. DELPINE1, G. DELEPINE1
(1Oncologic Department – Avicenne Hospital – Bobigny; 25 impasse du
bon Pasteur, Rouen, France)
Introduction: Few cases of periosteal Ewing’s sarcoma have been
reported and the surgical implications of such a diagnosis were not
underlined. The aim of this study is to evaluate the actual inci-
dence and consequence on surgery.
Diagnostic criteria: The reported cases fulfilled the diagnosis criteria
defined by Bator:
Ewing’s sarcoma of bone histologically confirmed but with a pure
periosteal location without medullary extension. In our practice,
the computed tomographies proved to be the most reliable exam
for diagnosis. Histology of resected specimen may ignore an initial
medullary involvement cured by preoperative chemotherapy. On
the opposite, M.R.I. can over estimate a PES with intense inflam-
matory reactive tissue inside the medullary canal.
Patients: Out of 132 Ewing’s sarcomas of bone of our file, only four
(3%) could be classified  as PES. All involved the  femur in the
diaphyseal (2) or metaphysodiaphyseal (2) locations. According to
Enneckling classification 2 tumours were graded IIA and 2 IIB.
Age of the patient ranged 11 to 18. All patients were treated by
resection after preoperative chemotherapy. None was irradiated.
With an average follow up of 7½ years, all 4 patients are in first
remission.
Review of the literature: With these 4 new cases, only 24 cases of
PES  of bone  have  been  described:  23  out  of  24  patients  were
located on long bones. All were stage II disease. All were treated by
chemotherapy and most by surgery (PES seem to have a better
prognosis than common form). 22 of 24 patients (91%) are in first
remission.
Discussion:  The  surgical  incidence  of  PES  must  be  underlined.
When the diagnosis is suspected, then biopsy should be confined
to  the  cortical  bone  without  medullary  contamination.  Such  a
procedure permits subsequent partial resection without interrup-
tion of the bone continuity, allowing much easier reconstruction.
Conclusion: Periosteal Ewing’s sarcoma is a rare entity that should
be recognized since there is prognosis and surgical incidence.
Cryosurgery in the treatment of low grade bone sarcoma.
preliminary results of six cases
DELEPINE GÉRARD1, DELEPINE FABRICE2, ALKALLAF
SALWA1, DELEPINE NICOLE1
(1Oncological Ped. Sce Hop. Avicenne France 25 passage du bon pas-
teur, Rouen, France)
Introduction:  Cryosurgery  has  been  used  extensively  for  many
aggressive or recurrent benign tumors but till now few cases were
described in treatment of bone sarcomas.
Patients: Five patients (4 males and 1 female aged 17–56 years)
with low grade bone sarcomas were treated by curettage and cryo-
therapy between March 1996 and July 2000. Histology was chon-
drosarcoma in 4 and multifocal epithelioid hemangioendothelioma
in  one.  As  the  patient  with  epithelioid  hemangioendothelioma
received  cryotherapy  for  2  locations,  6  different  tumors  were
treated: 2 proximal tibia, 2 distal femur, 1 os calci and one sacral
bone. Cryotherapy was preferred to classical treatment  by wide
resection to avoid amputation in 2 patients, extra-articular resec-
tion in 1, massive prosthesis in 1 and major neurologic sawquellae
in 1.
Method: Following intra-capsular curettage the residual cavity was
filled with liquid nitrogen. The freeze was maintained for several
minutes  and  then  allowed  to  thaw.  Freezing  and  thawing  was
repeated 2 or 3 times. In all the limb locations the cavity was then
filled with methacrylate and osteosynthesis performed to prevent
secondary fracture. After operation immediate mobilization and
full weight bearing were authorized. On August 1, 2000, median
follow up is 36 months.
Results: 2 skin sloughs (one followed by deep infection of os calci)
were observed and compelled  to  reoperate. The patient  with  a
chondrosarcoma of the sacrum suffered from painful paresthesia
during 6  months. No  fracture nor  recurrence was  observed  till240 Abstracts
now. According to the EMSOS criteria, the late functional score
was rated excellent in 3 patients and good in 2.
Conclusion: In selected low grade bone sarcoma, cryotherapy yields
oncologic results as good as marginal resection and permits much
more conservative surgery. Despite impredictability and complica-
tions of freezing, cryosurgery should be considered for low grade
intracompartimental  (grade IA) bone sarcoma. More cases  and
longer follow up are needed for definitive conclusions.
Parosteal osteosarcoma of the tarsus with vertebral metas-
tasis: a case report
FERNÁNDEZ SEARA P, ECHEGOYEN A, LÓPEZ COUSIL-
LAS A, REPÁRAZ B
(Dpt. of Pathology. Virgen del Camino Hospital. Pamplona. Spain)
Case report: A 49-year-old man who 6 years ago suffered a sprain in
the right ankle, and since then discomfort in the tarsus. In that
moment, a radiograph showed a hyperdense exofitic lesion in the
tarsal scaphoid that was diagnosed as hyperdense exostosis. Two
years later the discomfort persisted, and the radiograph showed an
increase in size. Four years later the patient was examined because
of an increase of the pain, and roentgenographically the lesion had
grown with an aggressive pattern, osteocondensed, suspicious of
malignancy. A biopsy  was  performed  and the  diagnosis was  of
Parosteal Osteosarcoma (PO). At the time of the biopsy the patient
developed back pain and the TAC revealed a destructive osteo-
condensed lesion  in  T8;  the  biopsy  was  identical  to  the  tarsal
lesion: PO.
Discussion: PO is a very rare neoplasm, accounting for less than 1%
of malignant bone tumors (7). The most common locations are
femur, tibia or humerus; the tarsal bones are unusual locations.
The pathologic diagnosis is very difficult, because they are well-
differentiated osteogenic tumors with only slight cytologic atypia,
and for this reason are required clinical and roentgenogram refer-
ences; the differential diagnosis may include diverse benign entities
such as Fibrous Dysplasia, Osteocartilaginous Exostosis, Parosteal
Osteochondromatous Proliferations, Ossificans Myositis, etc. The
treatment is conservative surgery, and the prognosis is very good
but metastases  have  been  described  in  very  unusual occasions.
Another special feature of this case is the synchronous diagnosis of
the two tumors with  identical histopathologic picture. Synchro-
nous bone tumors have been described in the literature, but in this
case we think the scaphoid lesion is a primary parosteal sarcoma
causing metastases in T8 vertebral body after 6 years of natural
development,  revealing  the  potentially  but  unusual  malignant
behavior of this neoplasm.
Conclusions:  PO  is  a  very  rare  neoplasm  among  bone  tumors.
Tarsal location is unusual. The prognosis is usually very good,
but we must remember its malignant biological nature, like this
case.
Osteoid  osteoma  treated  by  percutaneous  radiofrequency
ablation: the C.T.O.–florence experience
CAPANNA R*, MICHELIS B*, CALDORA P*, CAMPANAC-
CI D A*, BELTRAMI G*, MUGNAINI M*, MAZZA Eº
(Department of Orthopaedic Oncology. C.T.O. º Department of Radi-
ology; Careggi Hospital, Florence, Italy)
Percutaneous  radiofrequency  coagulation  has  become  a  highly
successful alternative to surgical treatment of the osteoid osteoma
(o.o.) using long wavelength electromagnetic radiation to produce
thermal ablation.
Materials and methods: From 1998, 19 patients underwent percuta-
neous radiofrequency ablation for o.o. in our Institution: 9 men
and 10  women, with  an average age of  28  years; 18  o.o. were
located in the limbs and 1 in D7 vertebral arch. Under CT guid-
ance a Kirschner wire was positioned inside the nidus with a hand
drill.  An  hollow  needle  biopsy  (8  gauge)  was  subsequently
advanced over the K wire and then utilised as a guide for the ther-
mocoagulating probe after removing the K wire. By using a 1 cm
tip length probe, attention should be taken to the final position
(confirmed by CT scan) since no more than 5 mm of tissue around
the probe will be burned. In benign tumors bigger than 1 cm, a 2
cm tip probe may be used or, in alternative, multiple coagulation
will  be  necessary.  In  our  experience  a  Radionics  Cool-tip  RF
Generator System has been used in all the patients. The electrode
is gradually brought to 90 degrees Cº working for 6 minutes on
average. Patients have been evaluated considering the pain relief
and  control  CT  examinations  were  performed  immediately
following the procedure and after 1, 6, 12 and 24 months.
Results: At an average follow up of twelve months (minimum 3 max
24) the procedure has been considered successful in 17 patients
(90%). In 2 cases there was no pain relief: 1 because an imaging
simulating an osteoid osteoma and 1 not responding to ablation
and undergone to surgical resection. Two minimal complications
were observed: both consisting in skin-burns. Hospitalisation time
has been of 24 hours in all cases.
Conclusion: Percutaneous thermocoagulation of the o.o. results to
be an effective, simple and minimally invasive technique in alter-
native  to  the  traditional  surgical  approach.  This  procedure  is
particularly indicated in osteoid osteoma deeply located, requiring
an aggressive surgical approach and for vertebral locations. In our
experience this procedure was successful in 90% of cases with no
major complications.
Management of giant cell tumours of the distal radius
KHAN M., GRAY J., CARTER S., GRIMER R., TILLMAN R
(Royal Orthopaedic Hospital Oncology Service. Birmingham, U.K)
Giant Cell Tumours of the distal radius are rare. Curettage has
been reported to be associated with high incidence of recurrence.
Twenty-three patients were referred to our unit over a 28 year
period  with  a  distal  radius  Giant  Cell  Tumour,  were  graded
according to the Campanacci system and underwent meticulous
curettage. Four patients developed recurrence, one of grade I,
and three grade III. Single curettage alone eliminated tumour in
19  patients  (82.6%) and 22 (95.7%) with a second curettage.
Complications occurred in 4 patients, all of which were grade III.
Carpal tunnel syndrome and ulnar impingement occurred in one
and two patients respectively, and required further surgery. One
patient underwent below-elbow amputation following repeated
curettage of a grade III tumour. Single curettage was curative in
17 of 18 patients (94.4%) with grade I or II tumours. Higher rates
of complications and recurrence occur in grade III tumours but
meticulous  curettage of early  lesions  offers the  best  chance of
cure.
Reconstruction  surgery  in  bone  tumours,  limb  salvage
surgery using autoclaved bone graft.
N. A. RIBEIRO, J. B. SALGUEIRO, J. S. AMARAL.
(Egas Moniz Hospital, Lisbon, Portugal.)
The authors have done a  retrospective  clinical  and radiological
study of four patients  with  malignant bone tumours  treated by
wide margin resection of the tumour, followed with reimplantation
of the resected autoclaved bone.
There was a male and three female patients with an average age
of 36.5 years (aged between 15–51 years). Histologically, threeAbstracts 241
were chondrosarcoma and the fourth a Ewing sarcoma. Resected
length of the proximal femur (two patients), distal femur (one
patient) and distal tibia (one patient), ranged from 10 to 23 cm.
After cartilage and soft tissue removal, the resected segment was
autoclaved for 8 minutes at 132ºC. A 0.2 megaPascal pressure
was used. None of the tumours recurred and at the most recent
follow-up (from 12 to 121 months with an average follow-up of
46.7 months), all the patients were disease free. All the patients
were  available  for  radiological  assessment  and  evident  bone
union was seen in three  cases. This method of reconstruction
using  autoclaved bone  graft  has  some  advantages  and can  be
useful in large bone resections,  along with  prosthetic  or other
implants. It seems to be a valid alternative to graft from bone
bank,  particularly  in  areas  where  complex  bone  morphology
(proximal  femur, for instance) makes  perfect  anatomical rear-
rangement with allograft difficult to achieve.
Shoulder surgery in malignant bone tumours
JOÃO B. SALGUEIRO, JORGE E. LOPES, NUNO A. RIBEI-
RO, RUI G. GORDO
(IPOFC de Lisboa/Hospital de Egas Moniz, 1990–2000)
The authors have done a retrospective clinical and radiological study
of  seven  patients  (four  females  and  three  males)  with  shoulder
malignant bone tumours operated between 1990 and 2000.
The median age was 43.3 years (17–59  years) and the  median
disease free interval was almost 5 years (5–137 months).
In  four  cases  the  histological  diagnosis  was  chondrosarcoma
(umerus – 3  patients, scapula – 1  patient), in one case mesen-
quimal  desdiferenciated  tumour  (scapula),  and  osteosarcoma
(umerus) and a Ewing sarcoma (scapula) in the other two cases.
The authors discuss  the  functional results,  the  morbility  of the
procedures, and the mortality.
ABSTRACTS FOR NURSES SYMPOSIUM
P.A.E. in children and adolscents with cancer experiencing
nutritional problems in patient and out patient protocol
E. MARIN, D. COLUNGA
(Pediatric Ward, Clinica Universitaria, University of Navarra. Pam-
plona, Spain)
Introduction: In recent years there have been significant advances
made in the treatment of cancer in children and adolescents. These
have improved survival rates but have also increased secondary
effects. From the nursing point of view and the experience of our
Paediatrics Department, we have found a significant deterioration
in the nutritional state of children and adolescents not only at the
diagnostic stage but also during treatment.
The occurrence of weight loss, nausea and vomiting, aversion to
food,  alteration  gustatory,  electrolyte  have  prompted  us  to
consider the need for a nursing protocol for in-patients and out-
patients established on the basis of a through assessment of the
nutritional-metabolical and elimination patterns in the child and
adolescent.
Aims: To detect the  most common nutritional problems during
treatment.
To establish a nursing care plan related to diagnosis.
To formulate a protocol for in-patients and out-patients.
Material  and  methods:  Descriptive  and  retrospective  study  of
nursing documentation in the light of the nutritional-metabolical
and elimination  patterns  established  by  M. Gordon and of the
problems  related  to  nursing  diagnosis  associated  with  these
patterns.
Our experience in terms of the assessment of continued nursing
care during diagnosis and treatment.
Discussion  and  conclusions: The need  to formulate  a  protocol to
counter the  nutritional  and metabolical  deficiencies  in  children
and adolescents as well as the problems related to elimination
Specific issues of children in hospital
G. CUGINO, M. MERCURI, M. MANFRINI
(5a Divisione  Chirurgica  Oncologica – Istituto Ortopedicao Rizzoli.
Bologna, Italy)
The surgical ward of the Department of Musculoskeletal Oncology
at  the  Istituti  Ortopedici  Rizzoli  specializes  in  the  surgery  of
neoplasms of bone and soft tissues. Nurses of this ward work with
patients  of  very  different  ages.  During  the  years  1998–99,  247
patients  aged  less  than  14  years  and 1591  adult  patients  were
admitted in this ward. Among the 247 pediatric patients, 48 under-
went major surgery (rotationplasties, vascularized graft, etc).
The aim of this study is to focus on the main problems of treating
and communicating with pediatric patients, according to:
– specific issues related to patients’ specificity:
￿ age and development: the ability of understanding the current
situation and the context vary in relation to the age of the chil-
dren, so  staff’s  explanations  and behaviour must  be chosen
accordingly;
￿ children behaviours: children have to move in a safe environ-
ment and the nursing-staff must be responsible for that;
￿  information: nurses must  know the  specific ways to interact
effectively with very young patients;
￿  employment of time: the possibilities to play, to move, and to
study are essential for these patients; parents may be involved
in these activities;
￿  stress:  the  disease,  the  therapy and the  clinical  tests  (blood
tests,  CT  scans,  MRI,  scintigraphy,  etc.)  together  with  the
interruption of normal life, all contribute to a very high level of
stress, which has to be controlled;
￿  pain.
– steps of diagnosis/treatment:
￿ hospitalization
￿  preparation to diagnostic procedures
￿  pre-operative preparation
￿  medication and plaster devices
The  protocolization  of  nursing  care  as  a  measure  to
diminish complications in the use of “implanted port”
M. REMIRO, P. MIGUELEIZ, S. PÉREZ
(Pediatric ward. Clínica Universitaria, University of Navarra. Pam-
plona, Spain)
Since year 1983, the Paediatric department of the C.U.N. used the
“implanted port” as a means of reaching the venous tract in chil-
dren with onco-hematologic diseases.
By studying 260 implanted ports in our Paediatric unity, as well as
revising the bibliography, we have found a series of complications
derived from the use of this system, principally obstructions and
infections.242 Abstracts
A protocol of nursing activities was elaborated based on a compar-
ative study. The application of this protocol allowed diminishing
the complications.
The comparative study and the protocol are presented with the
purpose of demonstrating its effectiveness.
Postoperative  pain  control  with  infusor  in  oncologic
patients
V. DELFINO, P. BONUCCELLI, F. ANEDDA, M. CARAVEL-
LA,  A.  CORAL,  C.  GRASSELLI,  M.  MARTINI,  N.  MOR-
RONE,  C.  NERI,  G.  PRINCIGALLI,  S.  ROSADI,  R.
SANTONI,  G.  SANTANGELO,  C.  SCIASCIA,  F.  TAN-
GANELLI, S. VICIANI
(Department of orthopaedic oncology and reconstructive surgery C.T.O.
Fiorence, Italy)
The aim of the study was the evaluation of the efficacy of analgesic
drug continuous delivery  by  an infusor  (elastomeric  pump)  for
postoperative pain control in patients undergoing surgical proce-
dures for bone or soft tissue tumours. From May to December
2000,  were  recruited  100  patients:  (47  females  and  53  males)
ranging in age from 16 to 80 years; 11 patients underwent ampu-
tation,  89  were  treated  by  resection  or  excision.  Limb  salvage
surgery was done in 43 soft tissue sarcoma and 46 bone tumours.
These patients were monitored by the nurses’ team following two
different protocols; a) analgesia by epidural infusor, b) analgesia by
intravenous  infusor.  Drugs  used  by  peridural  infusion  were
Morphine 20 mg, Marcaina 0.5% 50 ml. physiologic solution 50
ml. Drugs used by intravenous infusion were Morphine 20 mg.
Ketorolac trometamina 120 mg. Physiologic-solution 90 ml. The
level of analgesia was monitored every 3 hours along 48 hours after
surgery using the VAS score system. The efficacy of the analgesia
was judged considering the amount of additional FANS sommin-
istration: GOOD (30 mg/48 hours/ketorolac trometamina) FAIR
(60  mg/48  hours/ketorolac  trometamina)  POOR  (>60  mg/48
hours/ketorolac  trometamina).  The  pain  control  resulted  as
GOOD in 83% of patients, FAIR in 11% and POOR in 6% cases.
No major adverse reaction and no local or general complications
related  to  the  analgesic  treatment  occurred  (infections,  trom-
boflebity,  etc).  Respect  to i.v. administration  drugs delivery by
peridural catheter  showed major disadvantages: a higher  risk  of
incorrect  insertion  or  subsequent  displacement  of  the  catheter
particularly in case of excited patients or having several additional
sources of pain (as multiple metastases, respiratory distress, etc.).
The use of infusor (either i.v. or peridural) showed several advan-
tages: 1) professional autonomy of the nurse team. 2) rational use
and choice of the different drugs. 3) simple technique to perform
and to maintain. 4) easy monitoring of the level and continuity of
the analgesia. 5) excellent compliance by the patients. In conclu-
sion, the present protocol showed in most of cases an excellent
postoperative  pain  control,  improving  also  the  psychological
condition of the patients who feel himself constantly cared, and
followed.
Nursing psychological care to parents of children hospital-
ised with cancer
A.B. MUÑOZ, A. SARSOLA, A. TREVIÑO, S. LAFUENTE
(Pediatric Ward. University Clinic, University of Navarra. Pamplona,
Spain)
Research reveals that after diagnosis, hospitalisation is the second
most  stressful  event  for  families  having  a  child  with  a  chronic
condition.
Teamwork with an interdisciplinary approach has been found to be
necessary  in  order  to  meet  patients  and  their  families  needs
correctly.
Starting from this point, the review of the literature and the anal-
ysis  of  the  current  situation  of  our  patients  and  families,  the
nursing team from the paediatric war in the University Clinic of
Navarre has developed a group of activities. With this protocol we
pretend to help parents to face the illness  and hospitalisation of
their children, and in this was to improve, promote and achieve
their adaptation to this situation.
Can a relative “become” a good health worker in managing
the central venous catheter of the tumor patient? experience
of the rizzoli orthopaedic institute (bologna-italia)
C. FORNI, L. LORO, T. MAZZEI, C. BERGHELLI, A. BIOL-
CHINI, M. TREMOSINI, A. TREGGIANI, C. RASPANTI
(Department of musculo-skeletal tumors – Rizzoli Orthopaedic Insti-
tute. Bologna, Italy)
The chemotherapy unit for bone tumours is a ward of 12 beds in
the department of musculo-skeletal tumours in the Rizzoli Ortho-
paedic Institute – Bologna, Italy. Only 5% of the patients in the
center come from our region, the rest are from other regions or
abroad. These patients are affected by osteosarcoma or Ewing’s
sarcoma of the extremities. In 80% of cases a long-term central
venous catheter (CVC) is inserted not only to carry out cycles of
chemotherapy in the hospital but also to perform repeated blood
tests, intravenous therapies and transfusions needed at home. To
ensure that treatment is really effective and at the same time safe,
the parents of each patient are taught all the procedures to manage
the CVC at home. This is to enable blood to be taken, and infu-
sion,  medication  and  heparinisation  to  be  carried  out.  This  is
advantageous compared to putting these patients in the hands of
the family doctor or peripheral health structures that are often not
competent in the management of these devices. The nursing team,
backed up by doctors, have designed their own training course to
acquire the necessary know-how in order to teach people without
specific skills some complex healthcare procedures. Subsequently,
a training course was set up to relatives, which consists of a theo-
retical part and practical one. For theory written and audio-visual
material is used; for the practical lessons a small laboratory has
been equipped with a professional dummy and the material needed
for  simulations.  52  patients  entered in the  study between June
1999 and June 2000 infection rate decreased from 10.1% to 7.8%
malfunction from 43% to 23% and only 1.6% never used the CVC
at home compared to 7.5% the year before. The analysis of results
shows that the aims have been fulfilled.
A  support  group  for  young  adult  survivors  of  childhood
musculoskeletal cancer: concerns and dilemmas
L. BEN-AMI, R. BERTY, O. ARBEL, E. SINGER, I. MELLER,
P. ELAD
(Departments of Social Services, Psychiatry and Orthopedic Oncology.
Tel Aviv Sourasky Medical Center – Tel Aviv, Israel)
Nine young adult survivors of childhood musculoskeletal cancer
participated in a support group held in Tel Aviv Sourasky Medical
Center. Their age range was 19–25 years, and the average length
of time since diagnosis was six years. The group met once monthly
over a period of two years. The department’s social worker and
psychologist led the group. The head of the department and head
nurse also participated in the meetings. The aim of the support
group was to investigate how the diagnosis of cancer in the past
affected present day functioning. Emphasis was placed on aspectsAbstracts 243
relevant to the stage in the participant’s life cycle such as relation-
ships with members of the opposite sex and choice of occupation.
A central issue  in the group discussion was how much being a
survivor of childhood cancer becomes part of a person’s identity.
Another concern was the connection between personal acceptance
of any existing disability and acceptance of it by others. The fact
that three group participants were young Arab women helped facil-
itate a discussion of cultural differences in coping and adjustment.
The  participants  reported  that  the  meetings  helped  them  in
accepting their  past  trauma and in  learning appropriate coping
styles of behaviour of their current status. Our experience indicates
that  young  adult  cancer  survivors  can  benefit  from  a  support
group, that focuses on their current needs.
Centralized cytotoxic unit in a pharmacy service
T. GARCIANDIA, GARAYOA N, RUIZ DE LAS HERAS R,
URDANOZ MA JOSÉ, ELCARTE B.E
(Pharmacy  Service.  Clínica  Universitaria.  University  of  Navarra.
Pamplona, Spain)
The use of antineoplastic drugs has increased during the last years
as well as the awareness of the potential risk associated with their
manipulation, preparation and administration.
As a consequence, some scientific societies have developed guide-
lines to motivate the correct manipulation of these drugs.
Since the beginning of cytotoxic therapy Hospital Pharmacy Serv-
ices, as those responsible for the correct use of drugs, have pursued
the preparation of cytotoxics in centralized units. Their objectives
with these units have been to protect to be manipulated (aseptic
manipulation of the drug) as well as the manipulator (adequate
facilities and working techniques).
In this presentation we describe the main characteristics that cyto-
toxic centralized units of Pharmacy Services must have, measures
that are available for individual protection and working techniques.
Regarding facilities  it is essential to have an area with restricted
access, in which there must be a biological safety cabinet vented to
the outside and with negative pressure.
Individual protection kit includes impermeable gowns, mask and
thick gloves.
In order to obtain the maximum benefit from the above measures it
is important to have personnel adequately trained in: antineoplastic
drugs, working procedures in laminar airflow cabins, reconstitution
and dilution techniques, and the use of needles with de spike filters
(0.22 micres) or other mechanisms for aerosol avoidance.
In summary, Pharmacy Services have tried to warrantee the safety
of the patient (correct drug and dose, most convenient dilution,
sterile preparations) and that of the cytotoxic manipulator (use of
laminar airflow cabins, equipment for personnel protection, and
adequate training).